Genetic engineering is the alteration of genetic material by direct intervention in genetic processes with the purpose of producing new substances or improving functions of existing organisms. It is a very young, exciting, and controversial branch of the biological sciences. On the one hand, it offers the possibility of cures for diseases and countless material improvements to daily life. Hopes for the benefits of genetic engineering are symbolized by the Human Genome Project, a vast international effort to categorize all the genes in the human species. On the other hand, genetic engineering frightens many with its potential for misuse, either in Nazi-style schemes for population control or through simple bungling that might produce a biological holocaust caused by a man-made virus. Symbolic of the alarming possibilities is the furor inspired by a single concept on the cutting edge of genetic engineering: cloning.
HOW IT WORKS
Any discussion of genetics makes reference to DNA (deoxyribonucleic acid), a molecule that contains genetic codes for inheritance. DNA resides in chromosomes, threadlike structures found in the nucleus, or control center, of every cell in every living thing. Chromosomes themselves are made up of genes, which carry codes for the production of proteins. The latter, of which there are many thousands of different varieties, make up the majority of the human body's dry weight.
Although it is central to the latest advances in modern genetic research, DNA was discovered more than 130 years ago. In 1869 the Swiss biochemist Johann Friedrich Miescher (1844-1895) isolated a substance, containing both nitrogen and phosphorus, that separated into a protein and an acid molecule. He called it nucleic acid, and in this material he discovered DNA. Some 74 years would pass, however, before scientists recognized the function of the nucleic acid Miescher had discovered. Then, in 1944, a research team led by the Canadian-born American bacteriologist Oswald Avery (1877-1955) found that by taking DNA from one type of bacterium and inserting it into another, the second bacterium took on certain traits of the first. This experiment, along with other experiments and research, proved that DNA serves as a blueprint for the characteristics and functions of organisms.
THE DOUBLE HELIX.
Nine years later, in 1953, the American biochemist James D. Watson (1928-) and the English biochemist Francis Crick (1916-) solved the mystery of DNA's structure and explained the means by which it provides necessary instructions at critical moments in the course of cell division and growth. They proposed a double helix, or spiral staircase, model, which linked the chemical bases of DNA in definite pairs. Using this twisted-ladder model, they were able to explain how the DNA molecule could duplicate itself, since each side of the ladder is identical to the other; if separated, each would serve as the template for the formation of its mirror image.
The sides of the DNA ladder are composed of alternating sugar and phosphate molecules, like links in a chain, and consist of four different chemical bases: adenine, guanine, cytosine, and thymine. The four letters designating these bases—A, G, C, and T—are the alphabet of the genetic code, and each rung of the DNA molecule is made up of a combination of two of these letters. Owing to specific chemical affinities, A always combines with T and C with G, to form what is called a base pair. Specific sequences of these base pairs, which are bonded to each other by atoms of hydrogen, constitute the genes.
A four-letter alphabet may seem rather small for constructing the extensive vocabulary that defines the myriad life-forms on Earth. If one stops to consider the exponential operations involved, however, it is easy to understand how large the range of possibilities can become. For any sequence, there are four possibilities for the first two letters (AT, TA, CG, or GC) and four more possibilities for the second two letters. Thus, just for a four-letter sequence, there are 16 possibilities, and for each pair of letters added to the sequence, the total is multiplied by four.
To see where this might lead, imagine that you started with a penny and tried to quadruple your funds every day. The first day there would not be a dramatic increase, since you would have to earn only $0.04, and even by day 4 you would need only $2.56 to meet your goal. But as the quadrupling process continued, day by day the sums of money would get bigger ($655.36 on day 8) and bigger ($16,772.16 on day 12) and bigger ($687,194,767.36 on day 18). Given the fact that the human body contains an almost unfathomable number of genes, each of which may be between 2,000 and 200,000 base pairs long, one can begin to imagine just how large the number of possibilities would become.
Each one of these combinations has a different meaning, providing the code for all manner of specific traits, such as brown hair and blue eyes, dimples, unattached earlobes, and so on. Except for identical twins, no two humans have exactly the same genetic information. What follows are just a few facts about the human genome—that is, all of the genetic material in the chromosomes of the human organism:
Some Facts About the Human Genome
- The human body contains about 100 trillion cells.
- Each cell has a DNA code consisting of some 1.5 billion base pairs.
- The DNA in each cell, if stretched to its full length, would be 6 ft. (1.8 m) long—yet it fits into a space about 0.0004 in. (0.0001 cm) across, smaller than the head of a pin.
- If all of the DNA in the human body were stretched end to end, it would reach to the Sun and back more than 600 times.
- If a person attempted to recite the entire human genome, with all its base pairs, at the rate of one letter per second, 24 hours a day, it would take a century.
- Every second scientists working on the Human Genome Project are decoding some 12,000 letters of DNA.
- Our DNA is 98% identical to that of chimpanzees.
- Only 0.2% of all human DNA differs between individuals; in other words, people are 99.8% the same, and all the vast differences between people are a product of just 1/500th of the total DNA.
- Despite all that scientists know about DNA, a staggering 97% of all human DNA has no known function.
Principles of Genetic Engineering
Just as DNA is at the core of studies in genetics, recombinant DNA (rDNA)—that is, DNA that has been genetically altered through a process known as gene splicing —is the focal point of genetic engineering. In gene splicing, a DNA strand is cut in half lengthwise and joined with a strand from another organism or perhaps even another species. Use of gene splicing makes possible two other highly significant techniques. Gene transfer, or incorporation of new DNA into an organism's cells, usually is carried out with the help of a microorganism that serves as a vector, or carrier. Gene therapy is the introduction of normal or genetically altered genes to cells, generally to replace defective genes involved in genetic disorders.
DNA also can be cut into shorter fragments through the use of restriction enzymes. (An enzyme is a type of protein that speeds up chemical reactions.) The ends of these fragments have an affinity for complementary ends on other DNA fragments and will seek those out in the target DNA. By looking at the size of the fragment created by a restriction enzyme, investigators can determine whether the gene has the proper genetic code. This technique has been used to analyze genetic structures in fetal cells and to diagnose certain blood disorders, such as sickle cell anemia.
Suppose that a particular base-pair sequence carries the instruction "make insulin"; if a way could be found to insert that base sequence into the DNA of bacteria, for example, those bacteria would be capable of manufacturing insulin. This, in turn, would greatly improve the lives of people with type 1 diabetes, who depend on insulin shots to aid their bodies in processing blood sugar. (See Non-infectious Diseases for more about diabetes.)
Although the concept of gene transfer is relatively simple, its execution presents considerable technical obstacles. The first person to surmount these obstacles was the American biochemist Paul Berg (1926-), often referred to as the "father of genetic engineering." In 1973 Berg developed a method for joining the DNA from two different organisms, a monkey virus known as SV40 and a virus called lambda phage. Although the accomplishment was clearly a breakthrough, Berg's method was difficult. Then, later that year, the American biochemists Stanley Cohen (1922-) at Stanford University, and Herbert Boyer (1936-) at the University of California at San Francisco discovered an enzyme that greatly increased the efficiency of the Berg procedure. The gene-transfer technique developed by Berg, Boyer, and Cohen formed the basis for much of the ensuing progress in genetic engineering.
Big Business in DNA
Ever since the breakthrough discoveries of Watson, Crick, and others in the 1950s made genetic engineering a possibility, the new field has promised increasingly bigger payoffs. These payoffs take the form of improvements to human life and profits to those who facilitate those improvements. The possible applications of genetic engineering are virtually limitless—as are the profits to be made from genetic engineering as a business. As early as the 1970s, entrepreneurs (independent businesspeople) recognized the commercial potential of genetically engineered products, which promised to revolutionize life, technology, and commerce as computers also were doing. Thus was born one of the great buzzwords of the late twentieth century: biotechnology, or the use of genetic engineering for commercial purposes.
Several early biotechnology firms were founded by scientists involved in fundamental research: Boyer, for example, teamed up with the venture capitalist Robert Swanson in 1976 to form Genentech (Genetic Engineering Technology). Other pioneering companies, including Cetus, Biogen, and Genex, likewise were founded through the collaboration of scientists and businesspeople. Today biotechnology promises a revolution in numerous areas, such as agriculture. Recombinant DNA techniques enable scientists to produce plants that are resistant to freezing temperatures, that will take longer to ripen, that will develop their own resistance to pests, and so on. By 1988 scientists had tested more than two dozen kinds of plants engineered to have special properties such as these. Yet no field of biotechnology and genetic engineering is as significant as the applications to health and the cures for diseases.
MEDICINES AND CURES.
The use of rDNA allows scientists to produce many products that were previously available only in limited quantities: for example, insulin, which we referred to earlier. Until the 1980s the only source of insulin for people with diabetes came from animals slaughtered for meat and other purposes. The supply was never high enough to meet demand, and this drove up prices. Then, in 1982, the U.S. Food and Drug Administration (FDA) approved the sale of insulin produced by genetically altered organisms—the first such product to become available. Since 1982 several additional products, such as human growth hormone, have been made with rDNA techniques.
One of the most exciting potential applications of genetic engineering is the treatment of genetic disorders, which are discussed in Heredity, through the use of gene therapy. Among the more than 3,000 such disorders, quite a few of which are quite serious or even fatal, many are the result of relatively minor errors in DNA sequencing. Genetic engineering offers the potential to provide individuals with correct copies of a gene, which could make possible a cure for that condition. In the 1980s scientists began clinical trials of a procedure known as human gene therapy to replace defective genes. The technique, still very much in the developmental stage, offers the hope of cures for diseases that medicine has long been powerless to combat.
In 2001 scientists at the Weizmann Institute in Israel brought together two of the most exciting fields of research, biotechnology and computers, to produce the DNA-processing nanocomputer. It is an actual computer, but it is so small that a trillion of them would fit in a test tube. It consists of DNA and DNA-processing enzymes, both dissolved in liquid; thus its input, output, and software are all in the form of DNA molecules. The purpose of the nanocomputer is to analyze DNA, detecting abnormalities in the human body and creating remedies for them.
The Human Genome Project
At the center of genetic studies, with vast potential applications to genetic engineering, is the Human Genome Project (HGP), an international effort to analyze and map the DNA of humans and several other organisms. As discussed in the essay Genetics, the HGP began with efforts by the Atomic Energy Commission, a predecessor to the U.S. Department of Energy, to study the genetic effects of radioactive nuclear fallout. In 1990 the Department of Energy in cooperation with the National Institutes of Health (NIH), launched the project. At about the same time, the governments of the United Kingdom, Japan, Russia, France, and Italy initiated their own, similar undertakings, which are coordinated with American efforts.
The purpose of the project is to locate each human gene and determine its specific structure and function. Such knowledge will provide the framework for studies in health, disease, biology, and medicine during the twenty-first century and no doubt will make possible the cures for countless diseases. Although great strides have been made in gene therapy in a relatively short time, its potential usefulness has been limited by lack of scientific data concerning the multitude of functions that genes control in the human body. For gene therapy to advance to its full potential, scientists must discover the biological role of each of these genes and locate each base pair of which they are comprised.
A PROGRESS REPORT.
Scientists participating in the project have identified an average of one new gene a day, and this rate of discovery has increased. At the time of its establishment in 1990 (under the leadership of James D. Watson, who served as director until 1992), HGP was expected to reach completion by 2005. In 2002, however, the project's leadership predicted completion by some time in the following year. Along the way, they had discovered that the human genome, originally believed to include 100,000 to as many as 150,000 genes, actually consists of about 30,000 to 40,000 genes.
Both HGP and a private firm, Celera Genomics (founded 1998), had undertaken the study of the human genome, and in June 2000 the entities jointly reported that they had finished the initial sequencing of the three billion-odd base pairs in the human genome. By that point, researchers also had completed thorough DNA sequences for many other organisms. The basis for the latter undertaking is that humans share many genes with other life-forms. With the completion of initial sequencing, scientists working on the HGP undertook the effort of determining the exact sequence of the base pairs that make them up all human genes. Long before completion, the project had yielded some information. Some of the genes identified through the HGP include one that guides reproduction of the human immunodeficiency virus (HIV), which causes the acquired immunodeficiency syndrome, better known as AIDS (see Infectious Diseases). Researchers also have located a gene that predisposes people to obesity as well as genes associated with such inherited disorders as Huntington disease, Lou Gehrig disease (also called amyotrophic lateral sclerosis, or ALS), and some colon and breast cancers.
A World of Controversy
The HGP has numerous implications—and not all of them, in the minds of some critics, are positive. The NIH inadvertently created cause for concern when, in 1991, it attempted to patent certain forms of DNA. While patenting is touted as a necessary financial incentive for research initiatives, critics maintain that it restricts access to the information generated and to the use of those discoveries. That places a great deal of control in the hands of the private firm that funded the research and may limit the spread of real benefits that result from discovery.
Some scientists and politicians have raised the concern that the ability to produce detailed genetic information on people could give too much power to the people who possess that knowledge. Most states do not have laws protecting citizens against the misuse of genetic information, for instance, by employers and insurers. In the absence of effective legal remedies, genetic testing may be used to bar people from employment or insurance coverage. Insurers may even make mandatory testing a requirement for coverage. Existing laws may not be adequate to protect people's privacy: whereas the individual may be protected from having to provide potentially damaging genetic information, such information still can be obtained by testing the individual's relatives.
The idea of genetic information being used to control a person's destiny calls to mind all sorts of nightmarish images, such as those raised by the movie Gattaca (1997). Set in a dystopian, or anti-utopian, future, the film depicts a character who employs elaborate means to conceal his true identity in order to hold on to a job that otherwise would be forbidden to him because of his DNA. In fact, one does not have to go to fiction to find examples of societies and movements that have used genetics as a form of social control.
The most frightening example of this was Nazi Germany, which practiced mass murder not only of Jews and other ethnic and social groups but also of people who suffered from mental retardation or other "undesirable" traits. The purpose of DNA was discovered only a year before the collapse of the Nazi empire in 1945, and one can only imagine what Adolf Hitler and his minions would have done with this knowledge if they had had access to it. (DNA is one of several scientific and technological concepts that came to fruition at the end of World War II but which Hitler, fortunately, was unable to use to his advantage. Others include rocketry, nuclear weaponry, radar, computers, and television.)
Nazism was actually an especially repugnant version of a movement known as eugenics, which had its origins in the late nineteenth and early twentieth centuries. Based on the idea that populations could be improved by encouraging people with "positive" traits to reproduce while discouraging reproduction among those with less desirable traits, eugenics was at one time a mainstream movement whose adherents included the distinguished U.S. Supreme Court justice Oliver Wendell Holmes, Jr. (1841-1935).
The specter of eugenics raises the threat that a single human, or a group of humans, could "play God" with the lives of others. Another dramatic fear associated with genetic engineering is the threat that a genetically re-engineered virus could turn out to be extremely virulent, or deadly, and spread. There are other, more mundane questions of ethics: for instance, is it appropriate for scientists to establish private, for-profit corporations to benefit from discoveries they made while working for public-sponsored research institutions? No wonder, then, that the budget for the HGP in the United States includes a small allocation (3% of its total) toward study of the ethical, legal, and social implications (ELSI) of the project. The ELSI Working Group is charged with studying the issues of fairness, privacy, delivery of health care, and education. Meanwhile, there is a vast body of opposition to genetic engineering, biotechnology, and the HGP. And no aspect of the larger subject is more upsetting to certain individuals, as well as special interest groups, as that of cloning.
A clone is a cell, group of cells, or organism that contains genetic information identical to that of the parent cell or organism. It is a form of asexual reproduction (see Reproduction), and as such it is not as new as it seems; what is new, however, is humans' ability to manipulate cloning at the genetic level. The first clones produced by humans as long as 2,000 years ago were plants developed from grafts and stem cuttings. By cloning—a process that calls into play complex laboratory techniques and the use of DNA replication—people usually mean a relatively recent scientific advance. Among these techniques is the ability to isolate and copy (that is, to clone) individual genes that direct an organism's development.
THE PROMISE OF CLONING.
The cloning of specific genes can provide large numbers of copies of that gene for use in genetic and taxonomic research as well as in the practical areas of medicine and farming. In the latter field, the goal is to clone plants with specific traits that make them superior to naturally occurring organisms. For example, in 1985 scientists conducted field tests using clones of plants whose genes had been altered in the laboratory to generate resistance to insects, viruses, and bacteria. New strains of plants resulting from cloning could produce crops that can grow in poor soil or even underwater and fruits and vegetables with improved nutritional qualities and longer shelf lives. A cloning technique known as twinning could induce livestock to give birth to twins or even triplets, and on the environmental front cloning might help save endangered species from extinction.
In the realm of medicine and health, cloning has been used to make vaccines and hormones. It has become possible, by combining two different kinds of cells (such as mouse and human cancer cells), to produce large quantities of specific antibodies, via the immune system, to fight off disease. When injected into the bloodstream, these cloned antibodies seek out and attack disease-causing cells anywhere in the body. By attaching a tracer element to the cloned antibodies, scientists can locate hidden cancers, and by attaching specific cancer-fighting drugs, the treatment dose can be transported directly to the cancer cells.
EXPERIMENTS IN CLONING.
The modern era of laboratory cloning began in 1958 when the British plant physiologist F. C. Steward (1904-1993) cloned carrot plants from mature single cells placed in a nutrient culture containing hormones. The first cloning of animal cells took place in 1964, when the British molecular biologist John B. Gurdon (1933-1989) took nuclei from intestinal cells of toad tadpoles and injected them into unfertilized eggs. The cell nuclei in the eggs had been destroyed with ultra-violet light, but when the eggs were incubated, Gurdon found that 1-2% of the eggs developed into fertile, adult toads.
The first successful cloning of mammals occurred nearly 20 years later, when scientists in Switzerland and the United States successfully cloned mice using a method similar to Gurdon's approach. Their method required one extra step, however: after taking the nuclei from the embryos of one type of mouse, they transferred them into the embryos of another type of mouse. The latter served as a surrogate, or replacement, mother. The cloning of cattle livestock was tried first in 1988, when embryos from prize cows were transplanted to unfertilized cow eggs whose own nuclei had been removed. An even greater breakthrough transpired on February 24, 1997, with the birth of a lamb named Dolly in Edinburgh, Scotland. Dolly was no ordinary sheep: she was the first mammal born from the cloning of an adult cell. Thus, she had been produced by asexual reproduction in the form of genetically engineered cloning rather than by anything resembling a normal process. Nonetheless, she proved her own ability to reproduce the old-fashioned way when, on April 23, 1998, she gave birth to a daughter named Bonnie.
ARE HUMANS NEXT?
Though Dolly's and Bonnie's births excited hopes, they also inspired fears. If large mammals could be cloned, could humans? As early as 1993 an attempt had been made at cloning human embryos as part of studies on in vitro (out of the body) fertilization. The purpose was to develop fertilized eggs in test tubes and then to implant them into the wombs of women having difficulty becoming pregnant. These fertilized eggs, however, did not develop to a stage that was suitable for transplantation into a human uterus. Then, on October 13, 2001, scientists at Advanced Cell Technology in Worcester, Massachusetts, successfully cloned a human embryo. They had not created human life, as it might sound; what they had developed instead was a source for nerve and other tissues that could be harvested for use in medicine and research. Still, the news—overshadowed though it was in America, where people were still reeling from the September 11 terrorist attacks—was earth-shattering. Human cells had been reproduced, and once again it appeared that the production of human clones might be possible.
It is easy to understand how people might respond with alarm to such frightening news with alarm. Such fears have a great deal more to do with Hollywood than they do with science. In fact, the accomplishment of the Massachusetts firm, while impressive from a scientific standpoint, was fairly modest compared with the Frankenstein-like image presented by anti-genetic engineering scaremongers. "Cloned an embryo" actually sounds a great deal more dramatic than what the Massachusetts scientists achieved, with just one embryo reaching the size of six cells before the cells stopped dividing. This is hardly the beginnings of a clone army.
At any rate, the cloning practiced at the Massachusetts firm was therapeutic cloning, involving the production of genetic material for the treatment of specific conditions. It is a far cry from reproductive cloning, which entails implanting a cloned embryo in a uterus—and even that is still a long way from the clichéd image of clones produced in a test tube without any parents other than the biological material used to create them.
Such ideas are related much more closely to those highlighted in Aldous Huxley's 1932 novel Brave New World than they are to scientific realities. And even if humans wanted to develop such technology, it would be many, many years in the future. As for "creating life," to do so is probably not even possible; if it is, such an achievement is about as far off as travel to another solar system. This is not to say that all fears of cloning and genetic engineering are unwarranted; on the contrary, it is good to have a healthy level of skepticism. But it is also good to be an equal-opportunity skeptic and therefore to question ideas in the popular culture—including opposition to genetic engineering.
WHERE TO LEARN MORE
Barash, David P. Revolutionary Biology: The New, Gene-Centered View of Life. New Brunswick, NJ: Transaction Publishers, 2001.
Chadwick, Ruth F. The Concise Encyclopedia of the Ethics of New Technologies. San Diego: Academic Press, 2001.
"Cloning." New Scientist (Web site). <http://www.newscientist.com/hottopics/cloning/>.
Department of Energy Human Genome Program (Web site). <http://www.ornl.gov/hgmis/>.
Genetic Engineering and Cloning: Improving Nature or Uncorking the Genie? (Web site). <http://library.thinkquest.org/19697/>.
Genetics Education Center, University of Kansas Medical Center (Web site). <http://www.kumc.edu/gec/>.
Hyde, Margaret O., and John F. Setaro. Medicine's Brave New World: Bioengineering and the New Genetics. Brookfield, CT: Twenty-First Century Books, 2001.
Judson, Karen. Genetic Engineering: Debating the Benefits and Concerns. Berkeley Heights, NJ: Enslow Publishers, 2001.
National Human Genome Research Institute (Web site). <http://www.nhgri.nih.gov>.
Twenty Facts About the Human Genome. Wellcome Trust (Web site). <http://www.wellcome.ac.uk/en/genome/thgfac.htm>.
Wade, Nicholas. Life Script: How the Human Genome Discoveries Will Transform Medicine and Enhance Your Health. New York: Simon & Schuster, 2001.
Organic compounds made of carbon, hydrogen, oxygen, nitrogen, and (in some cases) sulfur bonded in characteristic formations. Strings of amino acids make up proteins.
A pair of chemicals that form the "rungs" on a DNA molecule, which has the shape of a spiral staircase.
A name for the industry built around the application of genetic engineering techniques.
A DNA-containing body, located in the cells of most living things, that holds most of the organism's genes.
A cell, group of cells, or organism that contains genetic in formationidentical to that of its parent cell or organism.
A specialized genetic process whereby clones are produced. Cloning is a form of asexual reproduction.
Deoxyribonucleic acid, a molecule in all cells, and many viruses, that contains genetic codes for inheritance.
A protein material that speeds up chemical reactions in the bodies of plants and animals without itself taking part in or being consumed by those reactions.
A unit of information about a particular heritable trait. Usually stored on chromosomes, genes contain specifications for the structure of a particular polypeptide or protein.
A process wherebyrecombinant DNA is formed by cutting a DNA strand in half lengthwise and joining it with a strand from another organism or perhaps even another species.
The introduction of normal or genetically altered genes to cells, typically to replace defective genes involved in genetic disorders.
Incorporation of new DNA into an organism's cells, usually with the help of a micro organism that serves as a vector.
A condition, such as a hereditary disease, that can be traced to an individual's genetic makeup.
The alteration of genetic material by direct intervention in genetic processes with the purpose of producing new substances or improving functions of existing organisms.
The control center of a cell, where DNA is stored.
Large molecules built from long chains of 50 or more amino acids. Proteins serve the functions of promoting normal growth, repairing damaged tissue, contributing to the body's immune system, and making enzymes.
Recombinant DNA, or DNA that has been genetically altered through gene splicing.
Enzymes that break DNA into fragments at particular sites.
In the context of genetics, a vector is a microorganism or virus that is used to transfer DNA from one organism to another.
"Genetic Engineering." Science of Everyday Things. 2002. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3408600134.html
"Genetic Engineering." Science of Everyday Things. 2002. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3408600134.html
GENETIC ENGINEERING is the deliberate manipulation of an organism's genetic makeup to achieve a planned and desired result. Proponents of genetic engineering consider it an extension of the selective breeding practiced for thousands of years in the domestication of agricultural products and animals. The genesis of modern biotechnology, most scholars agree, came in the early 1970s with the advent of recombinant DNA (rDNA). Since biotechnology often refers to the use of organisms in agriculture, industry, or medicine, its origins can be traced back to the use of yeast for baking bread and the fermentation of alcohol. The impact of contemporary genetic engineering and biotechnology affects nearly every area of human activity. The introduction of rDNA engineering has revolutionized our relationship to the organic world and to ourselves, demanding a reconsideration of our values, our notion of progress, and the morality of scientific research.
The History of Genetic Engineering
Genetic engineering owes its existence to the developments in molecular genetics, virology, and cytology that culminated in the determination of the structure of DNA by James Watson and Francis Crick in 1953. Building on research involving bacteriophages (a bacterial virus), Joshua Lederberg, a geneticist at the University of Wisconsin, found that bacteria can transfer genetic information through plasmids, small mobile pieces of DNA that exist independent of the chromosomes. In the 1950s, Lederberg pioneered the earliest techniques in genetic engineering, shuffling genetic material between bacterial cells. After the identification of restriction enzymes capable of "cutting" DNA in specific locations in 1968, scientists were able to insert foreign DNA directly into bacterial cells. The discovery that the foreign DNA would naturally bond with the host DNA, made it possible to splice together genes from multiple organisms, the technique used in recombinant DNA engineering. Although highly complicated, rDNA engineering can be simply explained: genetic material from the donor source is isolated and "cut" using a restriction enzyme and then recombined or "pasted" into the genetic material of the receiver. By 1971, advanced transplantation techniques had been developed and rDNA techniques using the restriction enzyme EcoRi were operable the following year, leading to the first experiments in genetic engineering.
In 1973, Stanford biochemist Stanley Cohen under-took one of the first rDNA experiments, inserting a piece of bacterial DNA into Escherichia coli (E. coli), a bacterium found in the human intestine. However, the research soon became controversial, particularly when American molecular biologist Paul Berg designed an experiment to insert DNA from simian virus #40 (sv40)—a known cancer-causing agent—into E. coli. As word of the daring procedure spread, the public was captivated and fearful, afraid that a genetically engineered virus, inured to antibiotics and carried in a common bacterium, could escape and cause an epidemic. Hoping to diffuse fears of a potential biohazard and maintain control of their research, over one hundred and fifty molecular biologists and related specialists met at the Asilomar Conference Center in Monterey, California, in late February 1975. The conference represented an extraordinary moment in the history of science, as the research community, recognizing its social responsibility, officially adopted a moratorium until appropriately safe procedures and guidelines could be developed. The conference ultimately resulted in the "National Institutes of Health Guidelines for Research Involving rDNA Molecules" and an ongoing National Institute of Health rDNA Advisory Committee (RAC)founded in 1974.
Yet the guidelines only increased public concern over genetic engineering. Critics charged that attempts to splice genes together from different organisms were akin to "playing God" and could result in dangerous and immoral hybrids. Adopting the literary example of "Dr. Frankenstein's monster" as an appropriate symbol of misguided science, opponents of rDNA engineering converged on research laboratories and public meetings. An attempt to build a recombinant laboratory at Harvard University set off such a firestorm that local politicians created a review board to assess potential risks, eventually requiring more stringent controls than those set by the NIH. By 1977, protests of rDNA facilities had spread to other campuses—the University of California San Diego, the University of Wisconsin, the University of Michigan, and the University of Indiana—while the state legislatures of New York, New Jersey, and California held public hearings. However, it was the resolution of an old court case and the introduction of a new form of rDNA engineering that ultimately created the greatest controversy.
In a monumental decision handed down on 16 June 1980, the United States Supreme Court held in Diamond v. Chakrabarty that man-made life forms were subject to patent laws and protection. The decision resolved a longstanding issue on patents and organic material, as the case dated to 1972, when Ananda Chakrabarty, a researcher at General Electric, applied for a patent on a form of Pseudomonas bacteria bred (but not genetically engineered)to digest oil slicks. By a narrow five to four margin the court construed the Patent Act, originally drafted by Thomas Jefferson, so as to include all products of human invention, relying on a 1952 Senate report that recognized as patentable "anything under the sun that is made by man." More than any other single event, the ruling galvanized many mainstream religious communities and environmental groups, eventually resulting in a letter of protest to President Carter and an indepth review by the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research (1980–1983). The commission's report, issued in 1982 and entitled Splicing Life: The Social and Ethical Issues of Genetic Engineering with Human Beings, emphasized the importance of rDNA engineering to biomedical progress and American industries, arguing that it was best that the research be conducted under the auspices of government regulation and control. However, while the study resolved anxiety over rDNA engineering and patenting, proponents of genetic engineering still had to address concerns over the development of "germ-line" engineering, a controversial procedure that allowed scientists to literally create new strains of organisms.
Germ-line engineering differs from rDNA engineering in that the donor genes are inserted into a "germ," or reproductive cell, thereby permanently altering the genetic makeup of the organism's descendants. For example, in 1982, Ralph Brinster of the University of Pennsylvania Veterinary School inserted the gene that produces rat growth hormone into mouse embryos. The resulting strain of mice, dubbed "super mice" by the press, expressed the gene and thus grew into a substantially larger and more powerful new breed of mouse. Critics of germ-line engineering quickly denounced the technique as immoral and argued it was a form of "anthropomorphic Lamarckism." Jean-Baptiste de Lamarck, a nineteenth-century French naturalist, had proposed that traits acquired during an organism's lifetime were passed on to its progeny—an idea refuted by Darwinian evolutionary theory. Yet, in germ-line engineering, traits acquired during the organism's lifetime are passed on, but only those traits deemed necessary or desirous by man. Environmental groups also denounced germ-line engineering because of "biosafety" concerns, fearing that genetically engineered species, which would possess a distinct advantage over nonengineered species, could upset the globe's finely tuned ecological systems. However, because most politicians, scientists, and manufacturers believed the potential benefits from rDNA and germ-line engineering outweighed its potential dangers, the protests were overshadowed by the development of a biotechnology industry based on genetic engineering.
Contemporary Applications of Genetic Engineering
The decision to allow patents on genetically engineered organisms, combined with the commission's sanction of rDNA engineering, and a national commitment to biomedical progress, led to tremendous growth in the biotechnology industry. In 1975, only five biotech companies participated in the Asilomar conference, by 1980 the number of similar companies had increased to one hundred. Today there are over 1,300 companies involved in genetic engineering, many of which are located in the United States, a clear indication of the rapid growth of the American biotechnology sector and the applicability of the powerful new techniques. Indeed, genetic engineering influences nearly every area of human activity, including agriculture and aquaculture, industry and environmental remediation, and the development of medicines and therapies.
Although agriculture has been one of the most successful industries in utilizing genetic engineering, the techniques have also made an impact in other areas of food production. In 1990, Chymosin, an enzyme necessary for cheese production, became the first genetically engineered food product to go to market. A few years later, in 1994, the Monsanto Company created a bovine growth hormone designed to stimulate milk production, a hormone now estimated to be given to 30 percent of dairy cows. The same year, the "Flavr-Savr" tomato developed by Calgene passed the Food and Drug Administration standards for genetically engineered foods and also went to market. Like many transgenic foods, the "Flavr-Savr" was designed to have increased shelf life and resist spoilage, although disputes regarding labeling and advertisements combined with high production costs caused the company to discontinue the product in the late 1990s. Nonetheless, genetic engineering is integrated into agriculture production; researchers estimate that as of 2001, nearly one-third of the corn and one half of the soybeans grown in the United States were transgenic. A study conducted in 2000 by the Grocery Manufacturers of America reported that the majority of processed foods sold in America contained transgenic ingredients. To help develop aquaculture, researchers at Johns Hopkins University have taken a gene from flounder and inserted it into both trout and bass in the hopes of making the fish more resistant to cold climates, thus increasing commercial and sport fishing.
Genetic engineering also has substantial applications in many other industries from plastics and energy to the new field of bioremediation. In 1993, Chris Sommerville, director of plant biology at the Carnegie Institute in Washington, D. C., successfully inserted plastic-making genes into a plant; the Monsanto Company hopes to market a cotton/polyester plant early in the twenty-first century. Scientists at numerous biotech companies are currently working on strains of E. coli bacteria capable of transforming agricultural refuse into ethanol, an efficient and clean source of energy. Genetic engineering is also aiding environmental clean-up through the emerging field of bioremediation—the use of organisms to reduce waste. Bacteria were employed to help with the Exxon Valdez oil spill in 1989, while scientists at the Institute for Genomic Research are among those hoping to engineer microbes that can detoxify waste, including radioactive materials. However, the fastest growing, and one of the most controversial, fields of biotechnology is applied human genetics, which includes transgenic medicines, xenotransplantation, and human gene therapy.
In 1982, Eli Lilly and Company began marketing bacterial-produced insulin, the first transgenic commercial product and an excellent marker of the industry's progress. Today, the vast majority of insulin used by Americans diabetics is genetically engineered and over 300 transgenic proteins and medicines are currently in production, many of which are made by animals. Indeed, animal "pharming" has been central to biomedical research and development since the introduction of genetic engineering; in 1988, Harvard University patented the "oncomouse," strains of mice missing or carrying specific genes and used in cancer research. In 1996, Genzyme Transgenics created a goat capable of producing anti-thrombin, an experimental anticancer drug; the following year PPL Therapeutics engineered a calf whose milk contains proteins necessary for nursing babies, including those born prematurely. Human hemoglobin, a protein essential for oxygen transportation in the bloodstream, can now be harvested from genetically engineered pigs. Transgenic pigs are also used in xenotransplantation, the transference of organs or parts from nonhuman species to humans. Nextran, a leading biotech company, hopes to use genetically engineered pig livers as temporary external reservoirs for patients suffering from acute liver failure. In the future, researchers hope that these transgenic medicines and proteins will help supplement human gene therapy, one of the boldest and most ethically and medically problematic areas of genetic engineering.
The history of human gene therapy is one of great promise and success mixed with controversy and stringent regulation. In the early 1980s, Martin Cline, a medical researcher at the University of California in Los Angeles, performed rDNA procedures in Italy and Israel on patients afflicted with hereditary blood disorders. Cline's unauthorized experimentation, although legal because the countries lacked genetic regulations, ultimately cost him funding and a department chairmanship. In response, the RAC established the Human Gene Therapy Subcommittee in 1984 to issue protocols and review applications. Years later, in 1990, researchers at the National Institute of Health (NIH)attempted the first approved human gene therapy for Ashanti DeSilva, a young girl forced to live inside a "bubble" because of severe combined immune deficiency, or ADA. As in most cases of human gene therapy, the researchers removed cells from the patient, genetically engineered the desired changes, and then replaced the cells. However, for ADA, as for most diseases, gene therapy offers only treatment, not a cure, as the procedure must be repeated periodically. Nonetheless, the success of Ashanti's procedure stimulated human gene therapy research; in 1992, Bernadine Healy, then director of the NIH, approved a "compassionate use exemption" to increase access to promising gene therapy trials for critically ill patients. Within a year, procedures had been approved for familial hypercholesterolemia, cystic fibrosis, and Gaucher's disease, and trials for cancer, AIDS, Parkinson's, Alzheimers, arthritis, and heart disease were being conducted. Unfortunately, the 1999 death from liver disease of Jesse Gelsinger, an eighteen-year-old student taking part in a University of Pennsylvania gene therapy trial, led to questions regarding the safety of established protocols, as the fatality resulted from a common immune reaction to the adenovirus vector (see Genetics) that the researchers could have easily anticipated.
Although genetic engineering remains in its infancy, the rapid development of the science and its related techniques has generated considerable disagreement in the attempt to address its moral and legal implications. The birth of the sheep "Dolly" in 1997, the first cloned adult mammal, led to debates over the sanctity of life and the individual, while the advent of human gene therapy has revived fears of eugenics programs and genetically engineered "designer" children. The marketing of transgenic foods stimulated the growth of an "organic" agricultural industry and created ongoing international disputes over patent rights, truth-in-labeling claims, and restrictions on genetically engineered imports. Some critics fear that xenotransplantation will promote the transference of animal diseases to humans, while others decry the use of animals simply for the benefit of mankind. The development of stem cell research, promising because the embryonic cells can be manipulated to become nearly any type of cell in the body, has led to protests by many pro-life organizations over the use of embryonic or fetal tissue; in August 2001, President Bush declared that only a limited number of cell lines were acceptable for federal research funding. Whether involved in human gene therapy, xenotransplantation, industry, or agriculture, genetic engineering and biotechnology will no doubt continue providing astounding advancements alongside heated controversy and debate well into the future.
Bud, Robert. The Uses of Life: A History of Biotechnology. New York: Cambridge University Press, 1993.
Fiechter, A., ed. History of Modern Biotechnology. 2 vols. Berlin: Springer Verlag, 2000.
Rifkin, Jeremy. The Biotech Century: Harnessing the Gene and Remaking the World. New York: Putnam, 1998.
Shannon, Thomas A., ed. Genetic Engineering: A Documentary History. Westport, Conn. : Greenwood Press, 1999.
Von Wartburg, Walter P., and Julian Liew. Gene Technology and Social Acceptance. Lanham, Md. : University Press of America, 1999.
"Genetic Engineering." Dictionary of American History. 2003. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3401801675.html
"Genetic Engineering." Dictionary of American History. 2003. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3401801675.html
Genetic engineering is the altering of an organism's deoxyribonucleic acid (DNA) to create a desired effect. Genetic engineers follow a set of techniques that allows them to remove genetic material from two or more species, recombine the genetic material (to create recombinant DNA), and integrate it into a host's genome, or genetic material. Genetic engineering is used for a variety of scientific, agricultural, and medical purposes.
All recombinant DNA technology requires the use of restriction enzymes. These enzymes are naturally occurring in bacteria that fight phage, or virus, DNA, but geneticists can use restriction enzymes as tools to cut DNA into manageable fragments.
Restriction enzymes recognize specific sequences along the DNA where it can be cut. These sequences contain four or more bases and occur randomly, and each enzyme cuts at a different sequence. Most restriction enzymes cut double-stranded DNA in a staggered fashion, so that a single strand extends from each end. These complementary "sticky" ends tend to bond to each other in solution.
Geneticists often need to isolate specific DNA molecules from a mixture. Restriction enzymes cut DNA into many small fragments. These fragments can be run through an electrophoretic gel, which distributes them according to size. In a technique known as Southern blotting, an absorbent membrane is then placed on the gel, transferring the ordered DNA fragments. Finally, a radioactive DNA probe is applied to the membrane, binding to any complementary DNA sequences and thereby labeling them.
Restriction enzymes can also be used to map genes. Restriction sites often vary by one or more nucleotides within a species. Genetic variation at a restriction site can produce a change in the length of a DNA sequence, also known as restriction fragment length polymorphism (RFLP). RFLP can then be measured, what is often called "DNA fingerprinting." Any genetic variation that is correlated with the RFLP is likely to be in the same part of the genetic material because correlations between distant genetic locations (loci) tend to break down over time as a result of recombination between chromosomes.
Making recombinant DNA requires isolating the DNA that will be cut, donor DNA, and the DNA into which the donor DNA will be inserted, vector DNA. The combination of donor DNA and vector DNA is recombinant DNA.
A vector is a small piece of DNA that carries the donor DNA into host cells. A common vector is a plasmid, a small ring of bacterial DNA that replicates independently of the main chromosome. Plasmids are useful vectors because they easily enter bacterial cells. A plasmid vector must first be removed from the rest of the bacterial genome. The DNA is removed and centrifuged so that the smaller plasmids sink farther than the larger chromosomes. Alternatively, an alkaline pH degrades genomic DNA but not plasmids, and the genomic DNA can be precipitated out of the solution.
Donor DNA and vector DNA must be digested with a restriction enzyme so that they can be spliced together. Some sticky ends will anneal (bind) vector DNA to donor DNA. Although their initial bonding is temporary, adding DNA ligase creates stronger bonds between the joined ends to make a continuous molecule.
To improve the efficiency of this procedure, annealing between two vector molecules or two donor molecules can be prevented by adding complementary nucleotides to one strand of each molecule, for example, As to the donor molecules and Ts to the vector molecules. Furthermore, two different restriction enzymes may be used for donors and vectors, allowing greater flexibility in choosing splice sites.
Plasmid vectors are introduced into bacteria by transformation. The plasmid replicates within each bacterium, and the bacteria divide many times. Consequently, a single DNA donor molecule can be amplified into billions of copies. This set of copies is referred to as a clone.
Most plasmids used to make recombinant DNA carry genes for drug resistance. This feature allows geneticists to apply an antibiotic to select bacteria that have been transformed by the recombinant plasmid. The antibiotics destroy bacteria that do not carry the plasmid. Plasmids also have particular restriction target sites that tailor them to the use of certain restriction enzymes. Vectors can have two different drug resistance genes, one of which contains the restriction site. If an insertion of donor DNA occurs, drug resistance is lost, and application of the drug will destroy all bacteria carrying the insert. In this way bacterial colonies carrying the desired gene can be identified and allowed to grow.
Lambda phage, a bacterial virus, can also be used as a cloning vector. Phage heads selectively package chromosomes about fifty kilobases in length. If a piece of phage DNA is removed and replaced by a donor DNA fragment of approximately the same size, the recombinant DNA can still be packaged. However, if the insertion is not successful, the phage head will not form and the DNA cannot be injected into bacteria. Successful transfection of donor DNA into a bacterial colony can be detected as a plaque indicative of infection.
There are several other types of vectors. Cosmids are hybrids of lambda phages and plasmids. Because they are larger than either phages or plasmids, they are capable of inserting larger DNA fragments. Expression vectors allow foreign genes produce proteins in a bacterium. Yeast artificial chromosomes (YAC) can carry very large inserts into yeast cells for replication. Bacterial artificial chromosomes (BAC) are capable of carrying large inserts into bacteria.
One goal of cloning genetic material is to develop a DNA library. A library is a collection of clones covering part or all of the genome of interest. It may consist of phage, bacteria, or yeast, depending on the vector used. A library may be genomic or cDNA. A cDNA library contains only coding DNA because it is synthesized from messenger RNA, which is the template from which proteins are made. A cDNA library is useful to researchers interested in genes that are expressed in particular tissues, from which they can obtain mRNA. Because the donor cDNA encodes protein, what is known as a cDNA expression library can also transcribe and translate genes into proteins.
Once a library is created, it can be screened with a probe to find a gene of interest. A probe is a piece of single-stranded DNA or an antibody that is radioactively labeled. A DNA probe will bind to a complementary strand of DNA in the library, whereas an antibody probe will bind to a protein. cDNA probes can be synthesized as an oligonucleotide, a short piece of synthetic DNA, from the amino acid sequence of the protein of interest. Because of the redundancy of the genetic code, many different cDNA's can code for the same protein. Therefore, a cocktail is often made of many different cDNA oligonucleotides.
Positional cloning is a process of using information about the location of a gene so as to clone it more efficiently. Clones can be ordered by their positions along a chromosome by doing a chromosome walk. A chromo-some walk uses the ends of each clone to probe the rest of the library for overlapping clones. If another gene is closely linked to the gene of interest and its position is known, only the clones near the first gene need be probed to find the gene of interest.
Tagging is a process in which a known DNA sequence (tag) is allowed to insert at random places in a genome. If by chance an insertion occurs in the gene of interest, it will likely cause a mutation that limits the functioning of the gene's product. Mutant lines are selected and used to construct a genomic library, which is then tested with the tag as a probe to identify the gene of interest.
Once a gene is cloned, its DNA sequence can be determined. First, the gene of interest is copied with a polymerase enzyme, a primer to direct the polymerase to the gene, and nucleotides. The nucleotides are not all the same, however. Some are missing an oxygen atom, which prevents them from adding another nucleotide to the end. Thus, the sequencing reaction results in an array of partial copies of the gene. If the reaction is performed with some deoxygenated thymine, then all of the copies will end in thymine. A different sequencing reaction can be performed for each deoxygenated base to generate four different sets of partial copies. The next step is to separate the partial copies according to size. Larger fragments travel more slowly through a gel, and mobility through an acrylamide gel is extremely sensitive to size. If one were to run two sets of fragments differing by just one base in size, the difference would be evident as two distinct bands on an acrylamide gel. Thus the products of a sequencing reaction will show up as an array of bands on an acrylamide gel, with each band representing the position of the deoxygenated nucleotide used in the sequencing reaction. Alternatively, just one sequencing reaction may be done with some of each nucleotide deoxygenated if each is labeled with a unique fluorescent dye, resulting in color-coded bands.
If the precise location of a gene is not known, sequencing can reveal its location. A functional gene usually appears as an open reading frame (ORF), which is a sequence of DNA uninterrupted by a stop signal. A sequence can be analyzed by a computer program, which examines all three possible reading frames on each strand. Unusually long ORFs indicate the presence of a gene, because otherwise stop codons are expected to appear at random.
If a gene has been cloned and sequenced, it can be copied from any individual in a population by polymerase chain reaction (PCR). Primers, short oligonucleotides that attach to complementary DNA and act as targets for the polymerase enzyme, are designed from the gene sequence. The strands of DNA are separated at a high temperature. The temperature is lowered again, one primer attaches to each strand of DNA, and the polymerase extends each one in opposite directions. This process is repeated many times by a machine, providing billions of copies of the gene in a few hours. PCR is useful for quickly amplifying DNA from many individuals in a population.
Gene Alteration and Expression
All of the above recombinant techniques allow geneticists to identify and describe genes. Once a gene has been sufficiently characterized, it can be manipulated to produce a desired outcome. In vitro mutagenesis can change a single target nucleotide to another nucleotide. First the gene is cloned into a single-stranded phage vector. An oligonucleotide primer is constructed from the gene's DNA sequence. The primer is complementary to the gene with the exception of the target site, which is changed to the desired nucleotide. (Although not completely complementary to the template DNA, hybridization occurs under certain conditions.) The phage is allowed to replicate so that its copy incorporates the new nucleotide. Continued copying will produce mostly mutant genes, which can be identified with the mutant primer as a probe under conditions that prevent hybridization with nonmutants.
Synthetic oligonucleotides can also be used to construct entire genes up to sixty bases in length. The automated reaction adds bases one at a time to the growing oligonucleotide, which is embedded in a resin. Overlapping oligonucleotides can be pieced together to synthesize longer sequences. Herbert Boyer's lab synthesized the gene for somatostatin, a human growth hormone, in this manner. The scientists added a restriction site to each end of the gene and a methionine codon to one end. Restriction enzymes were used to insert the gene into a bacterial plasmid that carried the same restriction sites. The insertion occurred in the middle of a bacterial beta-galactosidase gene, which the bacteria transcribed and translated. The resulting protein was a chimera (of genetically diverse tissue) of somatostatin and beta-galactosidase, separated by a methionine residue. Cyanogen bromide was used to cleave the protein at the methionine residue and recover the somatostatin.
There are other ways to produce eukaryotic (non-bacterial) gene products in bacteria. For example, phage T7 contains promoters that generate a large amount of protein during a late stage of infection. First, a gene is inserted next to a T7 promoter. The promoter interacts with T7 RNA polymerase, which is synthesized in the presence of lactose. Therefore, the addition of lactose to bacteria carrying the recombinant T7 will produce large quantities of the gene product. Insulin, somatostatin, and many pharmaceutical drugs are now produced with engineered bacteria and fungi.
Genetic engineering is not restricted to placing eukaryotic genes in bacteria. Eukaryotic cells can be altered by inserting foreign DNA into their genomes. An organism derived from such a cell is referred to as transgenic. There are several ways to produce transgenic organisms. For example, the gene of interest (the transgene) can be paired with a eukaryotic promoter in a vector and injected into the nucleus of the organism's gamete. The promoter will cause the gene to be expressed whenever the promoter's natural gene is expressed. This may be useful in determining the expression pattern of the natural gene if the product is not as easily detectable as that of the transgene. Or, the transgene's product alone may be valuable. For example, crops can be endowed with genes for pesticides or metabolizing nitrogen. Unfortunately, the ecological consequences of introducing transgenic organisms into nature are unknown.
Gene Therapy and Screening
Gene therapy is the insertion of a normal gene into a chromosome carrying a defective copy of the gene. The first case of gene therapy in a mammal was the cure of a growth hormone deficiency in mice. A gene was inserted into the ova of mice carrying two defective promoters for the gene. The gene was paired with a promoter-regulator for the metallothionein gene, which activates in the presence of heavy metals. Offspring carrying the transgene showed higher growth rates in the presence of heavy metals than did those without the transgene, indicating that a functional metal-lothionein promoter had taken control of the growth hormone gene.
Human gene therapy can be either germinal or somatic. Germinal gene therapy introduces transgenes into both somatic cells and germ line cells of the early embryo. This therapy has been performed on mice but not humans. Somatic gene therapy inserts transgenes only into affected tissues using a viral vector. This form of therapy has proven successful in treating severe combined immunodeficiency disease and atherosclerosis. Because most transgene vectors insert randomly throughout the genome, one potential side effect of gene therapy is a mutation caused by insertion into a healthy gene.
Although gene therapy for humans remains highly experimental, genetic screening for diseases is already being applied. Embryonic cells are collected from the amniotic fluid or the placenta. Some genetic abnormalities can be detected by their effects on restriction sites. A probe constructed from the cDNA of the gene of interest is used to identify fragments of DNA carrying the gene. These fragments are digested by a restriction enzyme whose target site contains the deleterious mutation. Mutant genes will not be cleaved by the restriction enzyme, whereas normal genes will. This can be detected as two different banding patterns on an electrophoretic gel. A related technique takes advantage of the often tight linkage between mutant genes and restriction fragment length polymorphisms (RFLP), which can serve as indicators for the presence of mutant genes.
PCR can also be used to amplify DNA for sequencing or another form of testing.
see also Genes; Genetically Engineered Foods; Genetics.
Brian R. West
Griffiths, Anthony J. F., et al. An Introduction to Genetic Analysis, 6th ed. New York: W. H. Freeman, 1996. Chapters 14 and 15.
Johnson, George B. Biology: Visualizing Life. New York: Holt, Rinehart and Winston, Inc., 1998.
West, Brian R.. "Genetic Engineering." Animal Sciences. 2002. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3400500154.html
West, Brian R.. "Genetic Engineering." Animal Sciences. 2002. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3400500154.html
Genetic engineering is any process by which genetic material (the building blocks of heredity) is changed in such a way as to make possible the production of new substances or new functions. As an example, biologists have now learned how to transplant the gene that produces light in a firefly into tobacco plants. The function of that gene—the production of light—has been added to the normal list of functions of the tobacco plants.
The chemical structure of genes
Genetic engineering became possible only when scientists had discovered exactly what is a gene. Prior to the 1950s, the term gene was used to stand for a unit by which some genetic characteristic was transmitted from one generation to the next. Biologists talked about a "gene" for hair color, although they really had no idea as to what that gene was or what it looked like.
That situation changed dramatically in 1953. The English chemist Francis Crick (1916– ) and the American biologist James Watson (1928– ) determined a chemical explanation for a gene. Crick and Watson discovered the chemical structure for large, complex molecules that occur in the nuclei of all living cells, known as deoxyribonucleic acid (DNA).
DNA molecules, Crick and Watson announced, are very long chains or units made of a combination of a simple sugar and a phosphate group.
Words to Know
Amino acid: An organic compound from which proteins are made.
DNA (deoxyribonucleic acid): A large, complex chemical compound that makes up the core of a chromosome and whose segments consist of genes.
Gene: A segment of a DNA molecule that acts as a kind of code for the production of some specific protein. Genes carry instructions for the formation, functioning, and transmission of specific traits from one generation to another.
Gene splicing: The process by which genes are cut apart and put back together to provide them with some new function.
Genetic code: A set of nitrogen base combinations that act as a code for the production of certain amino acids.
Host cell: The cell into which a new gene is transplanted in genetic engineering.
Human gene therapy (HGT): The application of genetic engineering technology for the cure of genetic disorders.
Nitrogen base: An organic compound consisting of carbon, hydrogen, oxygen, and nitrogen arranged in a ring that plays an essential role in the structure of DNA molecules.
Plasmid: A circular form of DNA often used as a vector in genetic engineering.
Protein: Large molecules that are essential to the structure and functioning of all living cells.
Recombinant DNA research (rDNA research): Genetic engineering; a technique for adding new instructions to the DNA of a host cell by combining genes from two different sources.
Vector: An organism or chemical used to transport a gene into a new host cell.
Attached at regular positions along this chain are nitrogen bases. Nitrogen bases are chemical compounds in which carbon, hydrogen, oxygen, and nitrogen atoms are arranged in rings. Four nitrogen bases occur in DNA: adenine (A), cytosine (C), guanine (G), and thymine (T).
The way in which nitrogen bases are arranged along a DNA molecule represents a kind of genetic code for the cell in which the molecule occurs. For example, the sequence of nitrogen bases T-T-C tells a cell that it should make the amino acid known as lysine. The sequence C-C-G, on the other hand, instructs the cell to make the amino acid glycine.
A very long chain (tens of thousands of atoms long) of nitrogen bases tells a cell, therefore, what amino acids to make and in what sequence to arrange those amino acids. A very long chain of amino acids arranged in a particular sequence, however, is what we know of as a protein. The specific sequence of nitrogen bases, then, tells a cell what kind of protein it should be making.
Furthermore, the instructions stored in a DNA molecule can easily be passed on from generation to generation. When a cell divides (reproduces), the DNA within it also divides. Each DNA molecule separates into two identical parts. Each of the two parts then makes a copy of itself. Where once only one DNA molecule existed, now two identical copies of the molecule exist. That process is repeated over and over again, every time a cell divides.
This discovery gave a chemical meaning to the term gene. According to our current understanding, a specific arrangement of nitrogen bases forms a code, or set of instructions, for a cell to make a specific protein. The protein might be the protein needed to make red hair, blue eyes, or wrinkled skin (to simplify the possibilities). The sequence of bases, then, holds the code for some genetic trait.
The Crick-Watson discovery opened up unlimited possibilities for biologists. If genes are chemical compounds, then they can be manipulated just as any other kind of chemical compound can be manipulated. Since DNA molecules are very large and complex, the actual task of manipulation may be difficult. However, the principles involved in working with DNA molecule genes is no different than the research principles with which all chemists are familiar.
For example, chemists know how to cut molecules apart and put them back together again. When these procedures are used with DNA molecules, the process is known as gene splicing. Gene splicing is a process that takes place naturally all the time in cells. In the process of division or repair, cells routinely have to take genes apart, rearrange their components, and put them back together again.
Scientists have discovered that cells contain certain kinds of enzymes that take DNA molecules apart and put them back together again. Endonucleases, for example, are enzymes that cut a DNA molecule at some given location. Exonucleases are enzymes that remove one nitrogen base unit at a time. Ligases are enzymes that join two DNA segments together.
It should be obvious that enzymes such as these can be used by scientists as submicroscopic scissors and glue with which one or more DNA molecules can be cut apart, rearranged, and the put back together again.
Genetic engineering procedures
Genetic engineering requires three elements: the gene to be transferred, a host cell into which the gene is inserted, and a vector to bring about the transfer. Suppose, for example, that one wishes to insert the gene for making insulin into a bacterial cell. Insulin is a naturally occurring protein made by cells in the pancreas in humans and other mammals. It controls the breakdown of complex carbohydrates in the blood to glucose. People whose bodies have lost the ability to make insulin become diabetic.
The first step in the genetic engineering procedure is to obtain a copy of the insulin gene. This copy can be obtained from a natural source
(from the DNA in a pancreas, for example), or it can be manufactured in a laboratory.
The second step in the process is to insert the insulin gene into the vector. The term vector means any organism that will carry the gene from one place to another. The most common vector used in genetic engineering is a circular form of DNA known as a plasmid. Endonucleases are used to cut the plasmid molecule open at almost any point chosen by the scientist. Once the plasmid has been cut open, it is mixed with the insulin gene and a ligase enzyme. The goal is to make sure that the insulin gene attaches itself to the plasmid before the plasmid is reclosed.
The hybrid plasmid now contains the gene whose product (insulin) is desired. It can be inserted into the host cell, where it begins to function just like all the other genes that make up the cell. In this case, however, in addition to normal bacterial functions, the host cell also is producing insulin, as directed by the inserted gene.
Notice that the process described here involves nothing more in concept than taking DNA molecules apart and recombining them in a different arrangement. For that reason, the process also is referred to as recombinant DNA (rDNA) research.
Applications of genetic engineering
The possible applications of genetic engineering are virtually limitless. For example, rDNA methods now enable scientists to produce a number of products that were previously available only in limited quantities. Until the 1980s, for example, the only source of insulin available to diabetics was from animals slaughtered for meat and other purposes. The supply was never large enough to provide a sufficient amount of affordable insulin for everyone who needed insulin. In 1982, however, the U.S. Food and Drug Administration approved insulin produced by genetically altered organisms, the first such product to become available.
Since 1982, the number of additional products produced by rDNA techniques has greatly expanded. Among these products are human growth hormone (for children whose growth is insufficient because of genetic problems), alpha interferon (for the treatment of diseases), interleukin-2 (for the treatment of cancer), factor VIII (needed by hemophiliacs for blood clotting), erythropoietin (for the treatment of anemia), tumor necrosis factor (for the treatment of tumors), and tissue plasminogen activator (used to dissolve blood clots).
Genetic engineering also promises a revolution in agriculture. Recombinant DNA techniques enable scientists to produce plants that are resistant to herbicides and freezing temperatures, that will take longer to ripen, and that will manufacture a resistance to pests, among other characteristics.
Today, scientists have tested more than two dozen kinds of plants engineered to have special properties such as these. As with other aspects of genetic engineering, however, these advances have been controversial. The development of herbicide-resistant plants, for example, means that farmers are likely to use still larger quantities of herbicides. This trend is not a particularly desirable one, according to some critics. How sure can we be, others ask, about the risk to the environment posed by the introduction of "unnatural," engineered plants?
The science and art of animal breeding also are likely to be revolutionized by genetic engineering. For example, scientists have discovered that a gene in domestic cows is responsible for the production of milk. Genetic engineering makes it possible to extract that gene from cows who produce large volumes of milk or to manufacture that gene in the laboratory. The gene can then be inserted into other cows whose milk production may increase by dramatic amounts because of the presence of the new gene.
Human gene therapy
One of the most exciting potential applications of genetic engineering involves the treatment of human genetic disorders. Medical scientists know of about 3,000 disorders that arise because of errors in an individual's DNA. Conditions such as sickle-cell anemia, Tay-Sachs disease, Duchenne muscular dystrophy, Huntington's chorea, cystic fibrosis, and Lesch-Nyhan syndrome result from the loss, mistaken insertion, or change of a single nitrogen base in a DNA molecule. Genetic engineering enables scientists to provide individuals lacking a particular gene with correct copies of that gene. If and when the correct gene begins functioning, the genetic disorder may be cured. This procedure is known as human gene therapy (HGT).
The first approved trials of HGT with human patients began in the 1980s. One of the most promising sets of experiments involved a condition known as severe combined immune deficiency (SCID). Individuals with SCID have no immune systems. Exposure to microorganisms that would be harmless to the vast majority of people will result in diseases that can cause death. Untreated infants born with SCID who are not kept in a sterile bubble become ill within months and die before their first birthday.
In 1990, a research team at the National Institutes of Health (NIH) attempted HGT on a four-year-old SCID patient. The patient received about one billion cells containing a genetically engineered copy of the gene that his body lacked. Another instance of HGT was a procedure, approved in 1993 by NIH, to introduce normal genes into the airways of cystic fibrosis patients. By the end of the 1990s, according to the NIH, more than 390 gene therapy studies had been initiated. These studies involved more than 4,000 people and more than a dozen medical conditions.
In 2000, doctors in France claimed they had used HGT to treat three babies who suffered from SCID. Just ten months after being treated, the babies exhibited normal immune systems. This marked the first time that HGT had unequivocally succeeded.
Controversy remains. Human gene therapy is the source of great controversy among scientists and nonscientists alike. Few individuals maintain that the HGT should not be used. If we could wipe out sickle cell anemia, most agree, we should certainly make the effort. But HGT raises other concerns. If scientists can cure genetic disorders, they can also design individuals in accordance with the cultural and intellectual fashions of the day. Will humans know when to say "enough" to the changes that can be made with HGT?
Despite recent successes, most results in HGT since the first experiment was conducted in 1990 have been largely disappointing. And in 1999, research into HGT was dealt a blow when an eighteen-year-old from Tucson, Arizona, died in an experiment at the University of Pennsylvania. The young man, who suffered from a metabolic disorder, had volunteered for an experiment to test gene therapy for babies with a fatal form of that disease. Citing the spirit of this young man, researchers remain optimistic, vowing to continue work into the possible lifesaving opportunities offered by HGT.
The commercialization of genetic engineering
The commercial potential of genetically engineered products was not lost on entrepreneurs in the 1970s. A few individuals believed that the impact of rDNA on American technology would be comparable to that of computers in the 1950s. In many cases, the first genetic engineering firms were founded by scientists involved in fundamental research. The American biologist Herbert Boyer, for example, teamed up with the venture capitalist Robert Swanson in 1976 to form Genentech (Genetic Engineering Technology). Other early firms like Cetus, Biogen, and Genex were formed similarly through the collaboration of scientists and businesspeople.
The structure of genetic engineering (biotechnology) firms has, in fact, long been a source of controversy. Many observers have questioned the right of a scientist to make a personal profit by running companies that benefit from research that had been carried out at publicly funded universities. The early 1990s saw the creation of formalized working relations between universities, individual researchers, and the corporations founded by these individuals. Despite these arrangements, however, many ethical issues remain unresolved.
[See also Birth defects; Chromosome; Diabetes mellitus; Gene; Genetic disorders; Genetics; Human Genome Project; Nucleic acid ]
"Genetic Engineering." UXL Encyclopedia of Science. 2002. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3438100324.html
"Genetic Engineering." UXL Encyclopedia of Science. 2002. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3438100324.html
The term genetic engineering refers to technologies that modify genes. Unlike selective breeding, which merely chooses traits that are already found in nature, genetic engineering acts directly on the genetic material itself in order to alter an organism's traits. Genetic engineering is the cornerstone of modern biotechnology, and through it human beings have the power to modify the molecular basis of all forms of life.
A brief history
The concept of genetic engineering emerged in the 1960s and was first realized in the 1970s. Its development depended upon a century of advances in science, beginning in the 1860s with Gregor Mendel's discovery of the existence of factors that govern inheritance. In the 1940s, it was learned that these factors, now called genes, are composed of a complex molecule, deoxyribonucleic acid or DNA. In 1953, Francis Crick and James Watson described the structure of DNA as the famous double helix along which are found pairs of chemicals. Soon it was learned that the sequence of these chemicals, known as bases, carries information that instructs the cell how to make proteins that are essential to the structure and function of the cell.
By the 1960s, it was becoming clear that scientists would soon learn how to manipulate this chemical information and thereby engineer genes. In the ensuing decades, various techniques for manipulating DNA have been developed, beginning in the early 1970s with the discovery of the use of restriction enzymes, which exist in nature and which cut and join strands of DNA at precise locations. This allows scientists to cut and splice DNA. A later discovery called polymerase chain reaction (PCR) made it possible for researchers to produce huge quantities of specific DNA sequences. Further advances in the use of computers to decode, store, and manipulate DNA means that researchers can discover and modify DNA on a broad scale and with considerable precision.
Genetic engineering uses various methods in pursuit of many goals. One method is to transfer a gene from one organism to another. For instance a human gene may be transferred to a microorganism in order to develop a new strain of microorganism that will produce a human protein, such as insulin, for pharmaceutical purposes. Much of the insulin used by diabetics comes from this process. It is possible in fact to transfer many genes into an organism by packaging them together as a kind of artificial chromosome, sometimes called a gene cassette. Plants, too, are genetically engineered to produce pharmaceutical products, to enhance their protein value as foods, to allow them to grow with less reliance on pesticides or fertilizers, to resist freezing or spoiling, to enhance flavor, or perhaps to grow in seawater. Another method is to incapacitate a particular gene by deliberately causing it to mutate and shut itself down. For instance if scientists know that an impaired human gene is linked to a disease such as cancer, they will find the corresponding gene in laboratory rats, shut it down, and create a strain of rats with this gene knocked out, and therefore with a high likelihood for cancer, in order to have animals on which to test possible therapies.
In human beings, scientists have attempted to modify or replace genes in some of the cells of patients' bodies in order to treat diseases with genetic basis. This strategy, called gene therapy, began in 1990 with mixed success. In time it will likely become widely used to treat a variety of diseases. Still another method is to modify a tiny portion of the gene—one or two bases of DNA—by constructing a special small molecule that can trigger what is called a mismatch repair. Ordinarily the body corrects for the mutations that occur naturally inside the body all the time, and scientists are learning how to exploit the body's own repair mechanisms to correct mutations that may have been inherited. These strategies used so far on human beings differ sharply from what scientists are attempting to do with other animals. In human beings, researchers are attempting to change the genes only in selected cells that are affected by the disease. In animals, however, the modifications affect every cell and are passed on to future generations. That strategy, often called germline modification, has been proposed for use on human beings but remains controversial from the standpoint of safety.
From the time genetic engineering was first considered in the 1960s, religious scholars and institutions have commented on its value and limits. Often scientists themselves, not to mention science journalists, report on developments in genetics in religious terms, speaking of DNA as the mystery of life or the human genome as the holy grail of biology. Not surprisingly, the general public sometimes responded to these developments with religious fervor, sometimes in favor of them, but often opposed to developments that people saw as, for instance, playing God.
One concern of special importance to many religious scholars and leaders has been the use of the system of patenting, by which governments give exclusive rights for a time to inventors, to protect developments in genetics. Particularly troubling has been the granting of patents to gene sequence information. Many have argued that knowledge of genes is discovery, not invention, and should not be eligible for patent protection. Many have also argued that granting biological patents amounts to patenting life, therefore making life a mere commodity. Other religious scholars recognize that patenting, while not perfect, is essential to the financial development of the full potential of genetic engineering, and that opposition to patenting is tantamount to opposing the benefits of research.
Beyond these general concerns, many religious scholars and organizations have considered developments in genetic engineering on a case-by-case basis. For instance, many religious organizations have responded to the use of genetic engineering to modify food by recognizing its potential for increasing the quality and quantity of food, but with cautions having to do with the viability of small farms, global inequities, the power of corporations in view of intellectual property rights, and the right of consumers to know what they are eating. Similarly, religious scholars have raised concerns, but generally have not objected categorically, to genetic engineering of animals. Of special concern is the prospect of herds of genetically identical livestock becoming vulnerable to disease, or to the use of genetic engineering to create strains of animals whose sole purpose is to suffer a disease for the benefit of medical research.
Quite understandably, human applications evoke the most intense religious responses. Religious responses to the use of genetic engineering for pharmaceutical purposes have been positive, with concerns limited to patenting, to the high costs of medicines, and to the need for socially just patterns of distribution. Furthermore, almost without exception, human gene therapy has met with approval not just by the public, but by religious institutions and scholars, who assess it morally as an extension of traditional medicine. Issues of safety remain, and many are concerned that the technique, when shown to be beneficial, will not be justly distributed.
The greatest concern, however, is that the technique will not be limited in its application to therapy but will be used for enhancement of human health and possibly of traits that are unrelated to health. Those who voice this concern point not just to cosmetic surgery and to performance enhancing drugs in sports but to the use of mood-altering pharmaceutical products, such as the drugs known as selective serotonin reuptake inhibitors (SSRIs). Evidence exists that people request these drugs not to treat anxiety or depression but to improve their mood and thus their performance in life. If that is true, some argue, how much more will people request gene modification that enhances their state of being and their performance. As of 2002, it is not at all clear which human traits will become susceptible to enhancement by genetic engineering. Height, most definitely, will be modifiable, but perhaps mental and emotional traits may be modifiable too. The concern here is the lack clarity about the distinction between therapy and enhancement, and thus the lack any publicly credible way to prevent those with economic or political means from acquiring new ways to improve themselves to the competitive disadvantage of others.
Sometime in the twenty-first century, many believe, humans will learn how to modify the genes of their offspring. Such germline modification, as it is usually called, is already done in other mammals, although not reliably. Many technical obstacles lie ahead, but learning to do this in human beings has a strong attraction, for some, in the promise that a family might be freed of a genetic disease that has afflicted it for generations. Other techniques, such as testing an embryo for disease before it is implanted, will probably achieve the same result at less cost and risk. If so, it may turn out that the real advantage of germline modification is not to eliminate disease but to improve the next generation, perhaps by enhancing resistance to disease or by producing other traits. The prospect of children born with such enhancement, often referred to as designer babies, is widely opposed by the general public, secular scholars, and religious leaders, even though most analysts concede that it probably cannot be prevented.
Religious objections to germline modification are that the resulting children will enter the world as objects, engineered according to the will of their designers and not as persons who emerge from the love of their parents. The intrusion of technology perverts the relationship between parent and child, difficult under any circumstance, but all the more so if parents can use technology to express their desires for the kind of child they want to have. Others believe that designed children will face impossible expectations in achieving that for which they are designed, and that they will likely resist their makers' intentions.
See also Biotechnology; Cloning; DNA; Eugenics; Gene Patenting; Gene Therapy; Genetically Modified Organisms; Genetics; Human Genome Project; Playing God; Stem Cell Research
bruce, donald, and bruce, ann, eds. engineering genesis: the ethics of genetic engineering in non-human species. london: earthscan, 1998
chapman, audrey r. perspectives on genetic patenting: religion, science, and industry in dialogue. washington, d.c.: american association for the advancement of science, 1999.
chapman, audrey r. unprecedented choices: religious ethics at the frontiers of genetic science. minneapolis, minn.: fortress press, 1999
chapman, audrey r., and frankel, mark s. human inheritable genetic modifications: assessing scientific, ethical, religious, and policy issues. washington, d.c.: american association for the advancement of science, 2000. available at http://www.aaas.org/spp/dspp/sfrl/germline/report.pdf
cole-turner, ronald. the new genesis: theology and the genetic revolution. louisville, ky.: westminster john knox press, 1993.
cole-turner, ronald. beyond cloning: religion and the remaking of humanity. harrisburg, pa.: trinity press international, 2001.
evans, john h. playing god? human genetic engineering and the rationalization of public bioethical debate. chicago: university of chicago press, 2002
hanson, mark j., ed. claiming power over life: religion and biotechnology policy. washington, d.c.: georgetown university press, 2001.
fletcher, joseph. the ethics of genetic control: ending reproductive roulette. garden city, n.y.: doubleday, 1974
kilner, john f.; pentz, rebecca d.; and young, frank e., eds. genetic ethics: do the ends justify the genes? grand rapids, mich.: eerdmans, 1997.
mackler, aaron, ed. life and death responsibilities in jewish biomedical ethics. new york: louis finkelstein institute and jewish theological seminary of america, 2000
national council of churches, panel on bioethical concerns. genetic engineering: social and ethical consequences. new york: pilgrim press, 1984.
peters, ted. playing god: genetic determinism and human freedom. new york: routledge, 1997.
peters, ted, ed. genetics: issues of social justice. cleveland, ohio: pilgrim press, 1998.
peterson, james c. genetic turning points: the ethics of human genetic intervention. grand rapids, mich.: eerdmans, 2001.
rahner, karl. "the problem of genetic manipulation." in theological investigations, vol. 9, trans. g. harrison. new york: seabury, 1966.
rahner, karl. "the experiment with man: theological observations on man's self-manipulation." in theological investigations, vol. 9, trans. g. harrison. new york: seabury, 1966.
ramsey, paul. fabricated man: the ethics of genetic control. new haven, conn.: yale university press, 1970.
shinn, roger lincoln. the new genetics: challenges for science, faith and politics. wakefield, r.i., and london: moyer bell, 1996.
willer, roger a., ed. genetic testing and screening: critical engagement at the intersection of faith and science. minneapolis, minn.: kirk house, 1998.
world council of churches, church and society. manipulating life: ethical issues in genetic engineering. geneva: world council of churches, 1982.
world council of churches, church and society. biotechnology: its challenges to the churches and the world. geneva: world council of churches, 1989.
COLE-TURNER, RONALD. "Genetic Engineering." Encyclopedia of Science and Religion. 2003. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3404200231.html
COLE-TURNER, RONALD. "Genetic Engineering." Encyclopedia of Science and Religion. 2003. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3404200231.html
GENETIC ENGINEERING. Genetic engineering involves the directed alteration of an organism's DNA (deoxyribonucleic acid)—that is, its genetic material. This technology has been applied to microbes, plants, and animals, and consequently used to modify foods, animal feedstuffs, and food-processing reagents.
Domestication and improvement of plants and animals for agriculture initially relied on identification of individuals with desirable characteristics from among natural populations. Applying knowledge of genetics to the breeding of plants and animals resulted in more rapid progress and remains vitally important to agricultural development. Traditional breeding, however, is constrained by the boundaries of sexual compatibility, which limits the choice of parents that can be used as sources of genes and traits to improve a specific crop or animal to those that can produce progeny through sexual reproduction. Genetic engineering expands the source of genes that can be used to modify the characteristics of plants and animals.
Technology of Genetic Engineering
Genetic engineering requires three fundamental technologies: the ability to isolate and modify the DNA of specific individual genes; an understanding of the mechanisms that regulate how genes function and how these can be manipulated; and the capacity to transfer genes into an organism. These have all been developed following the discovery of the structure of DNA in 1953. Genetic engineering of microbes was first reported in 1973, followed in the next decade by similar achievements in plants and animals. Because DNA is the genetic material in all organisms, genes for genetic engineering can be taken from any source, or even synthesized. Modification of genes may be necessary, particularly in regions that control how they operate, in order for the genes to function effectively in the recipient organism. Agrobacterium tumefaciens, a bacterium that transfers DNA into plant cells as part of its normal life cycle, is used commonly to transfer genes into plants, although other methods such as the "gene gun" also have been developed. Genetically engineered plants are technically "transgenic organisms," as they contain transferred genes. However, they are frequently referred to as "genetically modified organisms," or GMOs, and the products derived from them are described as "genetically modified," or GM foods. These terms can be confusing, as essentially all cultivated plants have been genetically modified through breeding and selection—for example, the many varieties of cultivated onions possess numerous qualities that distinguish them from each other and especially from the wild onions from which they originated.
Application of Genetic Engineering in Agriculture
The first genetically engineered crops were planted on a large scale in 1996. By 2001 more than fifty million hectares were planted worldwide with transgenic crops. The first generation of these crops has been altered in ways that improve the efficiency of crop production by modifying the tolerance of plants to herbicides and insect pests. Broad-spectrum herbicides are able to kill almost all plants. A prerequisite for using chemicals to control weeds in a crop is that the crop itself must be resistant to the herbicide. Genetic engineering has been used to develop plants (specifically soybean, canola, corn, and cotton) with resistance to two broad-spectrum herbicides, glyphosate and glufosinate, which are sold under the trademarks Roundup and Liberty, respectively. Glyphosate-tolerant soybeans have been adopted rapidly in some countries, notably the United States and Argentina, and accounted for approximately 46 percent of the soybean acreage worldwide in 2001. Herbicide use has not declined in these crops but the specific herbicides that are used have changed.
Insect pests can damage crops during the growing season and also after harvest. A variety of methods, including cultural practices and insecticides, are used to control insect damage. Genetic engineering has provided novel approaches to this problem. The bacterium Bacillus thuringiensis (Bt ) produces proteins that are toxic to some types of insects, and Bt spores have been used as insecticides for decades. Genes encoding Bt toxin proteins have been isolated, modified so they function in plants, and transferred into crop plants including corn, potato, and cotton. These engineered Bt crops are more resistant to such insects as the European corn borer, Colorado potato beetle, and cotton bollworm than are their nonengineered counterparts. The introduction of Bt cotton has resulted in reduced use of insecticides on this crop in some regions of the United States. Growers of Bt crops are required to plant a portion of their acreage with varieties that do not carry the Bt gene, in an effort to delay the development of insect populations with resistance to Bt toxins.
The Flavr Savr tomato, developed in the 1980s by Calgene, a biotechnology company in California, was the first food produced from a genetically engineered plant. These tomatoes ripened more slowly and had an extended shelf life. However, for a number of reasons—including production problems and consumer skepticism—this product was not a commercial success and was withdrawn in 1996, after less than three years on the market. Melons and raspberries have also been engineered to have delayed ripening but have not been produced commercially. Transgenic papayas with resistance to ring spot virus also have been developed. These were grown successfully in Hawaii, where the papaya industry was devastated by this debilitating disease. A similar approach was used to produce virus-resistant summer squash and against other viruses affecting a wide variety of foodstuffs.
The first generation of transgenic crops for the most part were designed to improve the efficiency of crop production, an ongoing objective for genetic engineers. Additionally, the techniques of genetic engineering can be used to alter the nutritional composition of foods. The transfer into rice of three genes that function to produce beta-carotene in the seed resulted in "golden rice." Once consumed, beta-carotene can be converted to vitamin A, the degree of this conversion being dependent upon a number of factors that relate to the source of the beta-carotene, the diet, and the individual consumer. In less-developed countries, vitamin A deficiency is widespread among those with a restricted diet, and is responsible for increased mortality and blindness in children. Although the efficacy of transgenic rice in reducing disease has not been established, it demonstrates the potential use of genetic engineering for nutritional enhancement in many crops. Other applications of genetic engineering of animal and human foods include removing allergens from foods such as peanuts, increasing the level of essential vitamins and nutrients in foods, and producing foods possessed of vaccines and other beneficial compounds.
Genetically engineered microbes also are used to produce proteins for food processing. Chymosin (or rennin), an enzyme used in cheese production, traditionally is obtained from the stomach of veal calves. However, the gene encoding this enzyme was transferred into microbes, and the enzyme now can be produced in bulk by purifying it from large microbe cultures. Chymosin prepared from transgenic microbes has more predictable properties than the animal product and is used to produce more than fifty percent of hard cheeses in the United States. Other enzymes used in food processing are produced by similar methods. For example, bovine growth hormone (BGH) is produced in large quantities from transgenic microbes and is given to cows to increase milk production.
Regulation of Genetic Engineering
In the United States, three federal agencies—Food and Drug Administration (FDA), Environmental Protection Agency (EPA), and Department of Agriculture (USDA) —are involved in regulating transgenic crops. Similar systems are in place in other countries as well. Companies that have developed this technology generally are supportive of the current regulatory framework. Nevertheless, the development of transgenic crops and the introduction of foods that contain products from these plants in the 1990s generated tremendous controversy, notably in Europe. Proponents of genetic engineering have argued that the addition of one or two well-characterized genes into crop plants that have a history of safe use is unlikely to affect materially the properties of these plants. Opponents suggest that this technology has not been tested adequately and the public should not be exposed to unknown and unnecessary food-based risks.
Safety concerns include the possibility that this technology will reduce the nutritional content of foods and introduce novel allergens or other toxins into foods. Opponents have sought more extensive testing and mandatory labeling of products that contain genetically engineered foods so that consumers can choose whether or not to eat such items. The impact of transgenic crops on the environment also has been questioned. Pests are likely to develop resistance to toxins produced by transgenic plants, raising doubts about the sustainability of this approach. However, transgenic technology also has the potential to reduce the use of chemical pesticides for crop production, which most regard as a positive development. Transfer of genes from engineered crops to other plants might also occur—for example, making weeds resistant to a specific herbicide or expanding the range of a plant so that it can grow in new locations.
This new technology also brings forth social, economic, and ethical issues, many of which are reflected by a wide political debate. One subject of concern is that most of the technology enabling genetic engineering of crop plants is controlled by a small number of companies. Much of this control is achieved through ownership of intellectual property, such as patents on genes, methods to produce transgenic plants, and the plant material that is the basis for crop improvement. Companies that manage agricultural inputs, such as seeds, pesticides, and fertilizers, as well as food processing and retail operations, function increasingly on a global scale. Opponents of globalization have criticized genetic engineering as one factor that is contributing to this trend and have expressed concern that both farmers and consumers will have limited choice in who supplies their needs. Opposition to genetic engineering also has come from religious groups who believe that tampering with genes in this way is unnatural—that is, inconsistent with the divine domain of nature—and should not be allowed.
Development of methods to genetically modify plants that extend beyond the limits of normal sexual reproduction has the potential to change many aspects of food production. Some of the first generations of products of this technology were adopted readily by most farmers but, as with other new technologies, there are many opponents. If this technology eventually receives widespread acceptance, it is likely that genetically engineered products will be found in almost everything that humans and domesticated animals eat.
See also Additives ; Agronomy ; Biotechnology; High-Technology Farming ; History of Food Production .
Charles, Daniel. Lords of the Harvest: Biotech, Big Money, and the Future of Food. Cambridge, Mass.: Perseus Publishing, 2001. A history of the development of agricultural biotechnology and genetically engineered foods.
Colorado State University. Transgenic Crops: An Introduction and Resource Guide. Available at http://www.colostate.edu/programs/lifesciences/TransgenicCrops/
Ervin, David, Sandra Batie, Rick Welsh, Chantal Carpentier, Jacqueline Fern, Nessa Richman, and Mary Schulz. Transgenic Crops: An Environmental Assessment. Morrilton, Ark.: Winrock International, 2000. Available at http://www.winrock.org/Transgenic.pdf
Nuffield Council on Bioethics. Genetically Modified Crops: The Ethical and Social Issues. London: Nuffield Council on Bioethics, 1999. A report from the United Kingdom that addresses consumer issues.
Pew Initiative on Food and Biotechnology. Harvest on the Horizon: Future Uses of Agricultural Biotechnology. Washington D.C.: Pew Initiative, 2001. Available at http://pewagbiotech.org/research/harvest/
Watson, James, Michael Gilman, Jan Witkowski, and Mark Zoller. Recombinant DNA. 2nd ed. New York: W. H. Freeman, 1992. A detailed description of the science behind genetic engineering.
Goldsbrough, Peter. "Genetic Engineering." Encyclopedia of Food and Culture. 2003. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3403400287.html
Goldsbrough, Peter. "Genetic Engineering." Encyclopedia of Food and Culture. 2003. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3403400287.html
The human manipulation of the genetic material of a cell.
Genetic engineering involves isolating individual DNA fragments, coupling them with other genetic material, and causing the genes to replicate themselves. Introducing this created complex to a host cell causes it to multiply and produce clones that can later be harvested and used for a variety of purposes. Current applications of the technology include medical investigations of gene structure for the control of genetic disease, particularly through antenatal diagnosis. The synthesis of hormones and other proteins (e.g., growth hormone and insulin), which are otherwise obtainable only in their natural state, is also of interest to scientists. Applications for genetic engineering include disease control, hormone and protein synthesis, and animal research.
International Codes and Ethical Issues for Society
An international code of ethics for genetic research was first established in the World Medical Association's Declaration of Helsinki in 1964. The guide prohibited outright most forms of genetic engineering and was accepted by numerous U.S. professional medical societies, including the american medical association (AMA).
In 1969 the AMA promulgated its own ethical guidelines for clinical investigation, key provisions of which conflicted with the Helsinki Declaration. For example, the AMA guidelines proposed that when mentally competent adults were found to be unsuitable subjects for genetic engineering studies, minors or mentally incompetent subjects could be used instead. The Helsinki Declaration did not condone testing on humans.
The growth of genetic engineering in the 1970s aroused international concern, but only limited measures were taken by governments and medical societies to control it. Concern focused on the production of dangerous bacterial mutants that could be used as harmful eugenics tools or weapons. The Genetic Manipulation Advisory Group was established in England based on the recommendations of a prominent medical group, the Williams Committee. Scientists were required to consult this group before carrying out any activity involving genetic manipulation in England. Additional measures required scientific laboratories throughout the world to include physical containment labs to prevent manipulated genes from escaping and surviving in natural conditions. These policies were subsequently adopted in the United States.
The Breakdown of Regulation: Genetic Inventions and Patents in the United States
In 1980 the Supreme Court created an economic incentive for companies to develop genetically engineered products by holding that such products could be patented. In Diamond v. Chakrabarty, 447 U.S. 303, 100 S. Ct. 2204, 65 L. Ed. 2d 144, the Court held that a patent could be issued for a novel strain of bacteria that could be used in the cleanup of oil spills. In 1986, the u.s. department of agriculture approved the sale of the first living genetically altered organism. The virus was used as a pseudorabies vaccine, from which a single gene had been cut. Within the next year, the U.S. patent and trademark office announced that nonnaturally occurring, nonhuman, multicellular living organisms, including animals, were patentable under the Patent Act of 1952 (35 U.S.C.A. § 101).
The Department of Agriculture formally became involved in genetic engineering in April of 1988, when the Patent and Trademark Office issued the first animal patent, granted on a genetically engineered mouse used in cancer research. U.S. scientists began experiments with the genetic engineering of farm animals, such as creating cows that would give more milk, chickens that would lay more eggs, and pigs that would produce leaner meat. These developments only raised more objections from critics who believed that genetic experimentation on animals violated religious, moral, and ethical principles. In spite of the controversy, the U.S. House of Representatives approved the Transgenic Animal Patent Reform bill on September 13, 1988. The bill would have allowed exempted farmers to reproduce, use, or sell patented animals, although it prohibited them from selling germ cells, semen, or embryos derived from animals. However, the Senate did not vote on the act and so it did not become law.
Significant State Laws
Certain states have passed laws restricting genetic engineering. By the early 1990s, six states had enacted laws designed to curb or prohibit the spread of genetically engineered products in the marketplace (see Ill. Ann. Stat. ch. 430, § 95/1 [Smith-Hurd 1995]; Me. Rev. Stat. Ann. tit. 7, § 231 et seq. [West 1995]; Minn. Stat. Ann. § 116C.91 et seq. [West 1995]; N.C. Gen. Stat. § 106-765-780 [Supp. 1991]; Okla. Stat. Ann. tit. 2, §§ 2011–2018 [West 1996]; Wis. Stat. Ann. § 146.60 [West 1996]). North Carolina's law sets the most comprehensive restrictions on genetic engineering. Resembling the earlier measures proposed by organizations such as England's Genetic Manipulation Advisory Group, it requires scientists to hold a permit for any release of a genetically engineered product out-side a closed-containment enclosure. The North Carolina statute has been cited as a possible model for advocates of comprehensive federal regulations.
In the mid 1990s the international guidelines established by the Declaration of Helsinki were modified to allow certain forms of cell manipulation in order to develop germ cells for therapeutic purposes. Scientists are also exploring genetic engineering as a means of combating the HIV virus.
In 1997 the cloning of an adult sheep by Scottish scientist Ian Wilmut brought new urgency to the cloning issue. Prior to this development, cloning had been successful only with immature cells, not those from an adult animal. The breakthrough raised the prospect of human cloning and prompted an international debate regarding the ethical and legal implications of cloning.
Since the cloning of the sheep, nicknamed "Dolly," scientists have found the process of cloning to be more difficult than expected. Since Dolly, scientists have cloned such animals as cows, pigs, monkeys, cats, and even rare and endangered animals. The process of cloning is complex, involving the replacement of the nucleus of an egg cell with the nucleus of a cell from the subject that will be cloned. This process is meticulous, and the failure rate is high.
In November 2001, scientists first successfully inserted the DNA from one human cell into another human egg. Although the eggs began to replicate, they died shortly after the procedure. Human cloning has caused the most intense debate on the issue, with the debate focusing upon scientific, moral, and religious concerns over this possibility. Scientists do not expect that human cloning will be possible for several years.
Evidence suggests that cloned animals have experienced significant health problems, leading to concerns about the vitality of the entire process. Cloned animals tend to be larger at birth, which could cause problems for the female animals giving birth to them. The cloned organisms also tend to become obese at middle age, at least in the case of experimental cloned mice. Moreover, evidence suggests that cloned animals have died because they do not have sufficient immunity defenses to fight disease.
Dolly lived for six years before dying in February 2003, which is about half of the normal life expectancy of a sheep. Proponents of the cloning experiments suggest that cloning opens a number of possibilities in scientific research, including the nature of certain diseases and the development of genetically-enhanced medications. Scientists have also successfully cloned endangered animals. In 2001, an Italian group cloned an endangered form of sheep, called the European mouflon. About a year and a half earlier, an American company, Advanced Cell Technology, tried unsuccessfully to clone a rare Asian ox. The cloning was initially successful, but the animal died of dysentery 48 hours after birth.
In 2000, a group of 138 countries, including the United States, approved the Cartagena Protocol on Biosafety Environment. International
concerns over the handling of genetically modified organisms (GMOs) prompted the passage of the protocol. It governs such issues as the safe transfer, handling, use, and disposals of GMOs among member countries.
Beauchamp, Tom L., and James F. Childress. 1983. Principles of Biomedical Ethics. New York: Oxford Univ. Press.
Darvall, Leanna. 1993. Medicine, Law, and Social Change. Aldershot, England; Brookfield, Wis.: Dartmouth.
Harder, Ben. 2002. "Scientific Pitfalls Complicate Cloning Debate." National Geographic.
Mason, John Kenyon, and R. A. McCall-Smith. 1994. Law and Medical Ethics. London: Butterworths.
——. 1987. Butterworths Medico-Legal Encyclopedia. London: Butterworths.
Paley, Eric R. 1993. "Rethinking Utility: The Expediency of Granting Patent Protection to Partial CDNA Sequences." Syracuse Law Review.
Ratnoff and Smith. 1968. "Human Laboratory Animals: Martyrs for Medicine." Fordham Law Review 36.
Smith, George P., II. 1993. Bioethics and the Law. Lanham, Md.: Univ. Press of America.
——. 1981. Genetics, Ethics, and the Law. Gaithersburg, Md.: Associated Faculty Press.
Trivedi, Bijal. 2001. "Human Embryos Cloned by U.S. Company, But Don't Survive." National Geographic.
"Genetic Engineering." West's Encyclopedia of American Law. 2005. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3437701974.html
"Genetic Engineering." West's Encyclopedia of American Law. 2005. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3437701974.html
Genetic engineering is the human altering of the genetic material of living cells to make them capable of producing new substances or performing new functions. The technique became possible during the 1950s when Francis Crick (1916-) and James Watson (1928-) discovered the structure of DNA molecules. Crick, Watson and later researchers learned how these molecules store and transmit genetic information.
DNA (deoxyribonucleic acid) is found in the nucleus of all living cells. It is structured as a double helix, with two twisted strands parallel to each other with rungs like a ladder between the strands. Each strand consists of four chemical bases: guanine (G), adenine (A), thymine (T) and cytosine (C). These bases are repeated in particular arrays of sequences throughout the DNA molecule. The patterns they create provide the instructions on how cells will develop and what their tasks will be. DNA is packed into structures called chromosomes within the cell.
Genetic engineering allows scientists to identify specific genes, remove them, and clone (duplicate) them and use them in another part of the same organism, or in an entirely different one. For instance, cells of bacteria colonies can be changed by genetic engineering to produce proteins, hormones or other substances that may be useful in treating illnesses in humans or other animals.
This process is called gene splicing or recombinant (as in recombining) DNA technique. Genetic engineers can also increase the amount of certain antibodies for treatment by using hybridomas (altered rapidly growing cancer cells and cells that make antibodies) to form monoclonal anti-bodies. They can also use the polymerase chain reaction technique to make perfect copies of DNA fragments from very small samples so that the origin of the substance (hair, blood) can be identified. This procedure is used in DNA fingerprinting in criminal cases.
Cloning and Engineering
Although the structure of DNA was discovered in the 1950s, it was not until the early 1970s that scientists figured out how to clone and engineer genes. The first experiments were done with simple organisms such as bacteria, viruses and plasmids (rings of free DNA in bacteria). Hamilton 0. Smith, Daniel Nathans and Werner Arber were the first researchers to realize that the bacteria made enzymes, called restriction enzymes, that would "cut" DNA chains in specific places. The scientists could then use these enzymes to cut the DNA into segments, cut out a segment that gave disease-causing instructions, and replace it with a segment that gave correct instructions for healthy functioning.
One could also use this technique to alter a bacterium to perform a certain function (such as making insulin for sugar metabolism) and then reproduce itself many times to provide this hormones for treating diseases such as diabetes. There are limits to this ability, however. Scientists must start with a complete organism, and cannot change everything in it. They can only make a limited number of changes, so the organism can remain essentially the same. Our knowledge of the total genetic code for humans, which contains millions of patterns is limited, so we cannot transfer complicated traits like intelligence, which are a mixture of genetic and environmental influences.
One of the most exciting potential applications of genetic engineering involves the treatment of genetic disorders. Medical scientists now know of about 3,000 disorders that arise because of errors in an individual's DNA. Conditions such as sickle-cell anemia, Tay-Sachs disease, Duchenne muscular dystrophy, Huntington's chorea, cystic fibrosis, and Lesch-Nyhan syndrome are the result of the loss, mistaken insertion, or change of a single nitrogen base in a DNA molecule.
Genetic engineering makes it possible for scientists to provide individuals who lack a certain gene with correct copies of that gene. For instance, in 1990 a girl with a disease caused by a defect in a single gene was treated in the following fashion. Some of her blood was taken, and the missing gene was copied and inserted into her own white blood cells, then the blood was returned to her body. If—and when—that correct gene begins to function, the genetic disorder may be cured. This type of procedure is known as human gene therapy (HGT).
Genetic engineering also promises a revolution in agriculture. It is now possible to produce plants that will survive freezing temperatures, take longer to ripen, convert atmospheric nitrogen to a form they can use, manufacture their own resistance to pests, and so on. By 1988 scientists had tested more than two dozen kinds of plants engineered to have special properties such as these. Domestic animals have been genetically "engineered" in an inexact way through breeding programs to create more meaty animals, etc., but with genetic engineering, these desirable traits could be guaranteed for each new generation of animal.
The potential commercial value of genetically-engineered products was not lost on entrepreneurs (business starters) in the 1970s. A few individuals believed that recombinant DNA would transform American technology as computers had in the 1950s. In many cases, the founders of the first genetic engineering firms were scientists themselves. They were profiting from research that was originally paid for in large part with government funds.
As a result, some have questioned whether individual scientists have the right to make a personal profit from these techniques. As of the early 1990s, working relationships had, in many cases, been formalized among universities, individual researchers, and the corporations they established. But not every-one is satisfied that the ethical issues involved in such arrangements are settled.
Many critics also worry about where genetic engineering might lead. If we can cure genetic disorders, can we also design individuals who are taller, more intelligent, or better looking? Is that a good application of the technology? Will the altered agricultural products be safe for humans, or will they change us in some unknown way? Will the altered bacteria used to create synthetic versions of substances such as insulin create new bacteria that are harmful to humans? Will humans know when to say "enough" to the changes that can be made? These are some of the ethical questions that surround genetic engineering.
Many other applications of genetic engineering have already been developed or are likely to be realized in the future. In every case, however, the glowing promises of each new technique are balanced by the new social, economic, and ethical questions that are being raised.
"Genetic Engineering." Medical Discoveries. 1997. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3498100129.html
"Genetic Engineering." Medical Discoveries. 1997. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3498100129.html
Genetic engineering is a discipline represented by the ability to isolate, modify the expression of, or transfer genetic material. Genetic engineering was born in 1973 when Stanley Cohen and Herbert Boyer reported the successful transfer of reptile DNA into bacteria. Practical applications quickly followed, and in 1980 Genentech became the first publicly traded genetic engineering company. Genentech's main product was human insulin produced in bacteria. It was marketed for diabetic patients who had developed allergies to the pig or sheep insulin used to treat diabetes. The enthusiastic response from investors led to many new genetic engineering companies. Many of the newest of their products are produced in genetically engineered animals. This practice is called pharming.
Insulin was just the first of many genetically engineered products. In 1995 there were over 100 genetically engineered therapeutic products approved by the U.S. Food and Drug Administration (FDA) or in clinical trials. They ranged from hormones like insulin and human growth hormone to vaccines, and included many products created to treat serious diseases such as muscular dystrophy, multiple sclerosis, and cancer. Genetic engineering has allowed scientists to explore genetic material in detail. In 2001 the preliminary report of the Human Genome Project was released, containing the nucleotide sequence of nearly all of the human genome (International Human Genome Sequencing Consortium 2001, pp. 860–921; Venter et al. 2001, pp. 1304–1351). A better understanding of human genetic makeup will allow scientists to understand both healthy cells and diseases better. Scientists are predicting that in a few years a patient will receive a DNA scan that will allow a doctor to prescribe medicines that match that patient's genetic makeup. These genetically tailored medicines are expected to be more effective and to have fewer side effects than their predecessors. A new scan technique called "DNA microarray" or "gene chip" is now available. With this technique a scientist or doctor can scan the identity of all the genes that a given tissue or cell is using at any time. This tool will be very powerful in helping to unravel the complex interactions of genes in diseases like cancer. It has already helped to identify the ways in which chemotherapy drugs interact, so that new more effective drug combinations may be developed. The same tool will help scientists to investigate cell growth and development. One important question that can now be asked is: Which genes are turned off or on as a cell ages?
One of the most exciting branches of therapeutic genetic engineering is human gene therapy. A single defective gene is often the cause of a disease, for example as with cystic fibrosis or sickle cell anemia. Gene therapy would allow doctors to transfer the healthy gene to the patient, and possibly allow replacement or removal of the harmful gene. For the first time doctors could cure genetic defects instead of being able only to treat the symptoms the defects cause. Trials of human gene therapy began in 1994 with some success (Anderson 1995, pp. 124–128), but much remains to be done before gene therapy can be used routinely. In addition, there are important ethical questions having to do with which genes will be identified as defective and which gene replacements will be allowed.
Agriculture is another area in which genetic engineering has become increasingly important. Many genetically engineered products are used in veterinary medicine and to enhance livestock-related production. For example, Bovine Somatotropin is used to increase milk production in dairy cows. It is becoming more common to use genetically engineered crops. Two of the most common examples are genetically engineered corn and beans. A kind of corn called Bt corn is engineered to contain and put to use a gene from a strain of bacteria that produces a toxin . This toxin kills insects that attack the corn so that farmers can use less insecticide on the field. Many soybeans are engineered to withstand a particular herbicide. Farmers can apply the herbicide to kill weeds in a planted field without harming the soybeans. All of these innovations have been very successful, but have provoked some concerns about human exposure to the new products, as well as new ecological concerns about "escape" of these genes into the environment. In one case Bt corn that had not been approved for human consumption accidentally made its way into human food products, and in another case the effects of Bt corn pollen on monarch butterflies have been questioned, but no answer is yet forthcoming. Genetically modified animals used to produce nonfoodstuffs such as those produced in pharming, and as laboratory models, are becoming more common.
see also Agricultural Chemistry; Chromosome; Clones; Genome; Recombinant DNA.
Anderson, W. French (1995). "Gene Therapy." Scientific American 273(3):124–128.
Berg, Paul, and Singer, Maxine (1992). Dealing with Genes: The Language of Heredity. Mill Valley, CA: University Science Books.
Biotechnology (1995). A pamphlet from the American Chemical Society Department of Government Relations and Science Policy. It can be ordered free online at <http://www.acs.org>.
Cohen, Stanley; Chang, A. C. Y.; Boyer, Herbert; et al. (1973). "Construction of Biologically Functional Bacterial Plasmids In Vitro." Proceedings of the National Academy of Sciences 70:3240–3244.
Friend, Stephen, and Stoughton, Roland (2002). "The Magic of Microarrays." Scientific American 286(2):44–53.
International Human Genome Sequencing Consortium (2001). "Initial Sequencing and Analysis of the Human Genome." Nature 409:860–921.
Maulik, Sunil, and Patel, Salil (1997). "Preface." In Molecular Biotechnology. New York: Wiley-Liss.
Scientific American (1997). "Making Gene Therapy Work." Scientific American 276(6):95–123.
Venter, J. Craig, et al. (2001). "The Sequencing of the Human Genome." Science 291: 1304–1351.
Human Genome Project. More information is available from <http://www.nhgri.nih.gov/HGP/>.
Speckhard, David. "Genetic Engineering." Chemistry: Foundations and Applications. 2004. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3400900215.html
Speckhard, David. "Genetic Engineering." Chemistry: Foundations and Applications. 2004. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3400900215.html
genetic engineering, the use of various methods to manipulate the DNA (genetic material) of cells to change hereditary traits or produce biological products. The techniques include the use of hybridomas (hybrids of rapidly multiplying cancer cells and of cells that make a desired antibody) to make monoclonal antibodies; gene splicing or recombinant DNA, in which the DNA of a desired gene is inserted into the DNA of a bacterium, which then reproduces itself, yielding more of the desired gene; polymerase chain reaction, which makes perfect copies of DNA fragments and is used in DNA fingerprinting; and any of several genome-editing techniques involving nucleases (enzymes that cut the bonds that join nucleotides), especially the CRISPR-Cas9 system, which can more easily edit or engineer genes and also has been used experimentally to activate and deactivate genes.
Genetically engineered products include bacteria designed to break down oil slicks and industrial waste products, drugs (human and bovine growth hormones, human insulin, interferon), and plants that are resistant to diseases, insects, and herbicides, that yield fruits or vegetables with desired qualities, or that produce toxins that act as pesticides. Genetic engineering techniques have also been used in the direct genetic alteration of livestock and laboratory animals (see pharming). In 2014 scientists at the Scripps Research Institute created genetically engineered Escherichia coli bacteria that included a pair of synthetic nucleotides, or DNA bases, in its genetic code. Genetically engineered products usually require the approval of at least one U.S. government agency, such as the Dept. of Agriculture, the Food and Drug Administration, or the Environmental Protection Agency.
Because genetic engineering involves techniques used to obtain patents on human genes and to create patentable living organisms, it has raised many legal and ethical issues. The safety of releasing into the environment genetically altered organisms that might disrupt ecosystems has also been questioned. The discovery in 2001 of genetically engineered DNA in native Mexican corn varieties made concerns of genetic pollution actual, and led some scientists to worry that the spread of transgenes through cross-pollination could lead to a reduction in genetic diversity in important crops. Transgenic rape (canola) plants also have been found in the wild in several countries. Imports of genetically modified corn, soybeans, and other crops have been curtailed or limited in some countries, and the vast majority of such crops are grown in just a handful of nations. The Cartagena Protocol on Biosafety, which has been signed by more than 100 nations and took effect in Sept., 2003, requires detailed information on whether and how imported seeds, plants, animals, other organisms, and the like are genetically modified and permits a nation to bar those imports, but a 2006 World Trade Organization decision treated the banning of genetically modified crops as a form of protectionism. The United States is not party to the 2003 treaty.
"genetic engineering." The Columbia Encyclopedia, 6th ed.. 2016. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1E1-genet-en.html
"genetic engineering." The Columbia Encyclopedia, 6th ed.. 2016. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1E1-genet-en.html
Humans have been modifying the genetic constitution (genomes) of crop plants for thousands of years, since the very beginning of agriculture. In the past, modifying the genomes of crop plants was accomplished by selecting seeds from those individual plants that produced the most grain, were most resistant to diseases, or were most tolerant of environmental stresses (e.g., drought). These seeds were then used to plant the next year's crop. This approach is sometimes referred to as classical plant breeding, and it has been extraordinarily successful at producing improved crops. However, this approach is subject to a major limitation in that it only allows for the selection of genes (and the associated genetic traits) that are already present in the genome of the crop plant. Although many potentially useful genes are present in the genomes of other organisms, they are not always present in the genomes of crop plants.
The limitations of classical plant breeding can be partially addressed by facilitating sexual reproduction between a crop plant and a wild plant species. This approach can be used to introduce new genes into a crop plant genome (e.g., genes for disease resistance). Unfortunately, sexual reproduction between crop plants and other species is restricted to closely related plant species, limiting the pool of potential genes that could be added to the crop plant genome. For example, commercially grown tomatoes (Lycopersicon esculentum ) may be able to reproduce sexually with wild tomato relatives (other members of the genus Lycopersicon ), but they would not be able to reproduce sexually with any wild (or domestic) member of the grass family (species within the family Poaceae). In addition, no human-directed mechanism for introducing genes into plants from other types of organisms (e.g., bacteria, fungi, mammals, etc.) was available prior to the advent of genetic engineering.
Plant genetic engineering has been developed to circumvent the limitations of classical plant breeding, allowing the addition of genes (i.e., segments of deoxyribonucleic acid [DNA]) from any organism to the genomes of crop plants. Plants to which one or more genes have been added through a means other than sexual reproduction are called genetically modified organisms (GMOs) or transgenic plants. The genes that are introduced into the plants are referred to as transgenes.
The Process of Genetically Engineering Plants
In order to achieve genetic engineering of plants, a series of tools and technologies are necessary. The ability to identify, isolate, and replicate specific genes is required. This series of steps is referred to as gene (or DNA) cloning. (A complete description of cloning is beyond the scope of this entry, but may be found in most biology textbooks.) A method to insert the cloned gene(s) into the genome of the crop plant is required, as is a method for identifying those cells that have incorporated the gene. The ability to regenerate entire plants from transgenic cells is essential, as is a means of verifying the presence of the transgene in the GMO.
Once a target gene has been cloned it is typically introduced into the genome of a crop plant by one of two means: Agrobacterium -mediated transformation or particle bombardment (biolistic) transformation. Agrobacterium tumefaciens is a very interesting soil bacterium that is a nonhuman "genetic engineer." Under natural circumstances, Agrobacterium has the ability to cause crown gall disease in some plants. The cause of the disease stems from Agrobacterium 's ability to insert some of its own genes into the genome of the plant. This results in the formation of a gall (tumorlike growth) on the plant and in the production of a food source, of which only the bacteria can make use. Deletion of the gall-inducing genes has allowed Agrobacterium to be used to produce many types of transgenic crop plants, including tomato, potato, and cotton.
Unfortunately, many important crop species are not easily susceptible to Agrobacterium -mediated transformation. The globally important cereal grains (such as corn, wheat, and rice) are prime examples of such species. Therefore, other approaches for introducing genes were developed. The most widely used is the particle bombardment technique. This technique involves accelerating small DNA-coated gold particles to a high velocity such that they are able to penetrate the cell walls of plant cells. Once inside the cell wall, some of the DNA is able to separate from the gold particles and integrate into the genome of the plant cell.
Regardless of whether the new DNA (transgene) is introduced by Agrobacterium or by particle bombardment, it is essential to understand that not all of the plant cells will contain the new gene(s). Therefore, a means of screening for the presence of the new DNA is required. Commonly, this is accomplished by including additional genes in the introduced DNA whose protein products confer resistance to a toxin that would normally kill plant cells. For example, the phosphinothricin acetyltransferase (PAT) gene confers resistance to the herbicide Basta. If a population of plant cells is bombarded with DNA that includes the PAT gene, and subsequently the cells are grown on a medium containing Basta, only those cells that contain the newly introduced transgenes will be able to grow.
The transgenetic cells must then be able to be regenerated into entire plants. This is accomplished through a series of steps referred to as tissue culture and makes use of plant hormones to stimulate the production of roots and stems from the transgenic cells. Various methods can be used to verify the continued presence of the transgene(s) in the regenerated plants. One method is to specifically amplify (thereby allowing easy detection) the DNA of the transgene using a technique called polymerase chain reaction (PCR).
An Example of a Genetically Engineered Crop Plant
To see how genetic engineering may be used to improve crops, let's look at a specific example. In the United States corn (maize) is attacked by an introduced insect pest called the european corn borer (ECB). This pest is a moth, and it is during the larval stage (the caterpillar stage) that it actually feeds on corn plants. Under some circumstances this pest can cause major damage to corn crops. There is also a naturally occurring species of bacterium (Bacillus thuringiensis ) that possesses a gene encoding a protein toxin (Bt-toxin) that is quite effective in killing many species of caterpillars. In addition, the Bt-toxin protein is not toxic to mammals, birds, and most other animals. Clearly, this Bt-toxin gene cannot be introduced into corn via sexual reproduction, as corn plants and bacteria are unable to reproduce sexually. However, genetic engineering provides an alternate approach to introduce the Bt-toxin gene into the genome of the corn plant.
The Bt-toxin gene has been cloned from Bacillus thuringiensis and introduced into the genome of corn plants using the particle bombardment approach. The resulting transgenic corn plants are resistant to ECB, and are, in fact, capable of killing ECB larvae that feed upon them. In essence, these transgenic corn plants are producing their own internal insecticide, allowing the farmer to plant corn without needing to subsequently apply chemical insecticides to prevent damage caused by ECB.
Potential Benefits and Concerns Regarding the Widespread Use of Genetically Engineered Crops
What are the potential benefits of planting transgenic corn producing the Bt-toxin? Potentially, the yield of corn may increase as corn plants are protected from ECB. Depending on market conditions and the cost of buying the Bt-toxin producing corn seed, this may or may not represent an economic benefit for corn growers. However, if the corn crop had been routinely sprayed with chemical insecticides to control ECB (true in some parts of the corn belt), then that economic cost to the farmer would be eliminated. In addition, the environmental costs of spraying a chemical pesticide, which can result in extensive killing of nontarget species, would be minimized. There have been, however, various concerns raised about the widespread use of Bt-toxin-containing corn, so we should also consider the potential dangers of applying this technology.
The potential concerns with widespread usage of Bt-toxin containing corn fall into three primary categories: direct health impacts of Bt-toxin on humans, selection for Bt-toxin resistant populations of ECB, and unintended environmental impacts. Bt-toxin-containing insecticides have been used for many years, and there have been no indications of direct toxic effects on humans. Nonetheless, there is the possibility that some individuals could develop allergic reactions to this protein. Widespread human use of transgenic corn containing Bt-toxin could potentially expose a much larger number of people to this protein.
Development of Bt-toxin-resistant populations of ECB is also certainly a major area of concern. Such insects would be able to feed on Bttransgenic corn and could potentially lead to increased populations of ECB. Other insects have demonstrated a remarkable ability to develop resistance to various insecticides (DDT-resistant mosquitoes, for example). Current approaches to minimize development of Bt-resistant ECB include planting mixtures of Bt-toxin containing corn and nontransgenic corn. The idea is to allow those corn borers that are susceptible to Bt-toxin to continue to reproduce, maintaining the presence of the susceptibility gene(s) in the ECB population. A related concern is that decreasing the population of ECB through widespread use of Bt-toxin-containing corn will result in a decline of the populations of other insects (principally types of wasps) that prey on ECB, reducing the potential for natural control of the ECB population.
The area of unintended environmental impacts is also of major concern. It is important to recognize that, while the Bt-toxin does not affect mammals or birds, it is toxic to many species of insects, not just ECB. Current commercially available Bt-toxin-containing corn varieties produce the toxin throughout the entire body of the plant, including the pollen grains. When a pollen grain is released from an anther it is dispersed by the wind in an attempt to reach the stigma (silk) of a female flower, but the vast majority of the pollen grains never reach a silk; they land somewhere else. If that somewhere else is a plant leaf that serves as a food source for another species of insect, that nontarget insect may be harmed or killed by the Bt-toxin. This concern has been specifically raised with regard to the monarch butterfly, whose caterpillars feed on milkweeds in and near corn fields; but there are, of course, many other species of moths or butterflies that could be potentially affected. Further studies are in progress to assess the impact of pollen-born Bt-toxin on monarch or other butterfly or moth species. One possibility to minimize this problem is to eliminate production of the Bttoxin in the pollen grains, while continuing production in those plant parts most affected by ECB, principally the stems and ears. This approach will necessitate the development of new varieties of Bt-toxin-containing transgenic corn that include the appropriate gene-regulating elements.
Clearly, the use of genetic engineering to modify crop plants has the potential to greatly benefit humans. Increased crop productivity could be used to feed the still-increasing population of humans on our planet. Increased production might also allow preservation, or restoration, of some natural areas that would otherwise be required for agricultural purposes. Other plant genetic engineering strategies may allow production of crops with improved nutritional qualities, the ability to synthesize industrial feed-stocks, resistance to various types of environmental stresses, or even the ability to produce drugs used in human medicine. However, as the Bt-toxin-containing corn example demonstrates, it is essential that we investigate, as thoroughly as possible, what unintended consequences may arise from use of the technology prior to widespread adoption of a particular type of transgenic crop plant.
see also Breeding; Genetic Engineer; Tissue Culture; Transgenic Plants.
James T. Colbert
Abelson, Philip H., and Pamela J. Hines. "The Plant Revolution." Science 285 (1999):367-68.
Campbell, Neil A., Jane B. Reece, and Lawrence G. Mitchell. Biology, 5th ed. Menlo Park, CA: Benjamin Cummings, 1999.
Della Penna, Dean. "Nutritional Genomics: Manipulating Plant Micronutrients toImprove Human Health." Science 285 (1999): 375-79.
Ferber, Dan. "GM Crops in the Cross Hairs." Science 286 (1999): 1662-66.
Moffat, Anne S. "Engineering Plants to Cope with Metals." Science 285 (1999):369-370.
Raven, Peter H., Ray F. Evert, and Susan E. Eichhorn. Biology of Plants, 6th ed. New York: W. H. Freeman and Company, 1999.
Colbert, James T.. "Genetic Engineering." Plant Sciences. 2001. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1G2-3408000149.html
Colbert, James T.. "Genetic Engineering." Plant Sciences. 2001. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1G2-3408000149.html
"genetic engineering." World Encyclopedia. 2005. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O142-geneticengineering.html
"genetic engineering." World Encyclopedia. 2005. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O142-geneticengineering.html
"genetic engineering." A Dictionary of Biology. 2004. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O6-geneticengineering.html
"genetic engineering." A Dictionary of Biology. 2004. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O6-geneticengineering.html
MICHAEL ALLABY. "genetic engineering." A Dictionary of Zoology. 1999. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O8-geneticengineering.html
MICHAEL ALLABY. "genetic engineering." A Dictionary of Zoology. 1999. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O8-geneticengineering.html
MICHAEL ALLABY. "genetic engineering." A Dictionary of Plant Sciences. 1998. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O7-geneticengineering.html
MICHAEL ALLABY. "genetic engineering." A Dictionary of Plant Sciences. 1998. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O7-geneticengineering.html
MICHAEL ALLABY. "genetic engineering." A Dictionary of Ecology. 2004. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O14-geneticengineering.html
MICHAEL ALLABY. "genetic engineering." A Dictionary of Ecology. 2004. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O14-geneticengineering.html
"genetic engineering." A Dictionary of Nursing. 2008. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O62-geneticengineering.html
"genetic engineering." A Dictionary of Nursing. 2008. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O62-geneticengineering.html
MICHAEL ALLABY. "genetic equilibrium." A Dictionary of Plant Sciences. 1998. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O7-geneticequilibrium.html
MICHAEL ALLABY. "genetic equilibrium." A Dictionary of Plant Sciences. 1998. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O7-geneticequilibrium.html
MICHAEL ALLABY. "genetic equilibrium." A Dictionary of Ecology. 2004. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O14-geneticequilibrium.html
MICHAEL ALLABY. "genetic equilibrium." A Dictionary of Ecology. 2004. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O14-geneticequilibrium.html
ge·net·ic en·gi·neer·ing • n. the deliberate modification of the characteristics of an organism by manipulating its genetic material.
"genetic engineering." The Oxford Pocket Dictionary of Current English. 2009. Encyclopedia.com. (August 26, 2016). http://www.encyclopedia.com/doc/1O999-geneticengineering.html
"genetic engineering." The Oxford Pocket Dictionary of Current English. 2009. Retrieved August 26, 2016 from Encyclopedia.com: http://www.encyclopedia.com/doc/1O999-geneticengineering.html